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CHAPTER I
INTRODUCTION
Anatomy of the Human Breast
The breast organs are endocrine glands that comprise mammary epithelial cells,
adipose tissue and connective tissue. The mammary glands are immature during
childhood and mature during puberty. The mammary gland is a complex network of
lobes and ducts. There are about 15-20 lobes in each mammary gland and each lobe is
made up of 20-40 lobules. Lobules produce milk after birth and the ducts help to carry
the milk to the nipple (PP. 2001, SK. 2014)
Mammary stem cells are vital for the development of the mammary gland. A
common progenitor cell is believed to give rise to two different types of epithelial cell
lineages – luminal (ductal and alveolar subtypes) and myoepithelial (or basal). The
regenerative capacity of the mammary epithelium during the reproductive cycles, as
well its expansion during puberty and then pregnancy suggests a critical role of stemlike cells (Shackleton, Vaillant et al. 2006). Also, serial transplantation of epithelial
regions of mouse mammary glands suggests that a single cell can reform the entire
mammary gland (Kordon and Smith 1998). Moreover, a mouse mammary gland is
progenitor cell-enriched (Welm, Tepera et al. 2002, Alvi, Clayton et al. 2003) and human
mammary glands contain cells that can form myoepithelial as well as luminal cells in
vitro (Stingl, Eaves et al. 2001, Gudjonsson, Villadsen et al. 2002, Dontu, Abdallah et al.
1
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2003). It is hypothesized that transformation of the stem cell or luminal or basal
progenitor cell compartment due to environmental insult or mutations leads to breast
cancer (Petersen and Polyak 2010).
Breast Cancer
According to World Health Organization, breast cancer is the most common form
of cancer among women worldwide. In the United States (U.S.), breast cancer is the
second leading cause of cancer-related deaths among women, followed by lung cancer.
It is estimated that about one in eight women in the U.S. would be diagnosed with
breast cancer in her lifetime. The American Cancer Society estimates that 252,710 new
cases of invasive breast cancer and 63,410 new cases of ductal carcinoma in situ
(DCIS) will be diagnosed in the U.S. in 2017. Approximately, 40,610 women in the U.S.
are estimated to die due to breast cancer in 2017 (Siegel, Miller et al. 2017).
Risk Factors for Breast Cancer
Various risk factors for breast cancer have been reported. Like most other forms
of cancer, age is a primary risk factor for breast cancer. The American Cancer Society
reported that, invasive breast cancer is diagnosed in women over the age of 55
(Howlader N). Listed below are the other risk factors for breast cancer:
Breast Cancer Risk Factors That Are not Under Personal Control.
Menstrual History: Women who have had more menstrual cycles because they
started menstruating early (before age 12) (Kelsey and Bernstein 1996) or because they
went through menopause later (after age 55) (1997) have slightly higher risk of breast
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cancer. The increased risk may be due to longer lifetime exposure to the hormones
estrogen and progesterone.
Race and Ethnicity: Rates of breast cancer vary in the U.S. by race and ethnicity.
White women have the highest incidence (rate of new breast cancer cases) overall,
while Asian-American, Native Hawaiian and Pacific Islander women have the lowest
(Howlader N).
Breast Density: Women with higher breast density are 4-5 times more likely to
get breast cancer than women with low breast density (Boyd, Guo et al. 2007,
Yaghjyan, Colditz et al. 2011).
Family History: Having a first-degree relative (male or female) with breast cancer
or a first-degree female relative with ovarian cancer increases the risk of breast cancer
(Pharoah, Day et al. 1997, Kharazmi, Chen et al. 2014).
Radiation Exposure: Women who as children or young adults were treated
with radiation therapy to the chest for another cancer have higher risk of breast cancer
(Guibout, Adjadj et al. 2005, Ibrahim, Abouelkhair et al. 2012).
Genetic risk factors. Although age and many other factors combined are risk
factors that contributes to development of breast cancers, there are clear genetic factors
that increase risk of developing breast cancer. Mutations or loss of expression of Breast
Cancer Associated1 and 2 (BRCA1 and BRCA2) genes are highly penetrant mutations
that increase the risk of breast cancer by 50-90% (Taucher, Gnant et al. 2003). Under
normal conditions, BRCA1/2 acts as a critical tumor suppressor by contributing to DNA
repair during cell cycle progression and transcription. However, when BRAC1/2 is
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mutated or lost, this loss of function leads to inefficient DNA repair during proliferation
and accumulation of subsequent mutations. Eventually this leads to evasion of cell
death signals and hyper-proliferation, ultimately leading to malignant transformation and
cancer. Women with the BRCA1 mutation have 55-65% chance of developing breast
cancer, whereas women with the BRCA2 mutation are at about 45% risk of breast
cancer (Antoniou, Pharoah et al. 2003, Chen and Parmigiani 2007). Mutations in genes
such as ataxia telangiectasia mutated (ATM), phosphatase and tensin homolog
(PTEN), TP53, cell cycle checkpoint kinase 2 (CHEK2), cadherin-1 (CDH1), serinethreonine kinase 11 (STK11) and partner and localizer of BRCA2 (PALB2) have been
detected but are not associated with increased risk of breast cancer (van der Groep,
van der Wall et al. 2011).
Lifestyle-Related Breast Cancer Risk Factors.
Lifestyle also plays a critical role and unhealthy lifestyle certainly contributes to
breast cancer.
Alcohol Consumption: Excessive alcohol consumption increases the risk of
breast cancer, and other cancers as well. Having 2-5 drinks daily increases the chances
of breast cancer occurrence by 1.5 times (Hamajima, Hirose et al. 2002).
Obesity and Physical Activity: Being obese or overweight after menopause
enhances breast cancer risk, as more fat tissue after menopause can raise the estrogen
levels (Huang, Hankinson et al. 1997, van den Brandt, Spiegelman et al. 2000).
Physical activity reduces the risk of breast cancer. Brisk walking for 1.25-2.5
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hours/week has been shown to reduce the risk of breast cancer by 18% (Eliassen,
Hankinson et al. 2010, Hildebrand, Gapstur et al. 2013, Wu, Zhang et al. 2013).
Hormone Therapy after Menopause: Estrogen plus progestin increases the risk
of developing and dying from breast cancer (Rossouw, Anderson et al. 2002, Manson,
Chlebowski et al. 2013). Estrogen alone was found to slightly decrease the risk of
breast cancer after short-term use(Chen, Manson et al. 2006). However, long-term use
of estrogen (for more than 10 years) has been found to increase the risk of breast
cancer(Brinton, Richesson et al. 2008).
Having Children: Women who have not had children or who had their first child
after age 30 have a slightly higher breast cancer risk overall (Bernstein 2002). Having
more children lowers the risk of breast cancer (Ewertz, Duffy et al. 1990, Lambe, Hsieh
et al. 1996, Nelson, Zakher et al. 2012).
Subtypes of Breast Cancer
Breast cancer is a heterogeneous disease and is categorized into various
subtypes, each one with distinct biological features that determine the course of
treatment and clinical outcome. There are five molecular subtypes of breast cancer:
i. Luminal A
ii. Luminal B
iii. Human Epidermal Growth Factor Receptor 2 (HER2)
iv. Triple negative/basal like
v. Normal like breast cancer
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Approximately 75% of breast cancers express steroid receptors, estrogen
receptor (ER) and/or progesterone receptor (PR). ER positive tumors express ER
responsive genes which include, -PR and the genes that code for proteins found in
luminal epithelial cells. For this reason, ER positive tumors comprise the luminal
subgroup (Yersal and Barutca 2014). There have been numerous classifications of the
luminal subtype based on gene expression analysis. Hu et al. created a data set based
on the gene cluster analysis of three independent studies and established two subtypes:
Luminal A and Luminal B (Hu, Fan et al. 2006), which was further validated by
subsequent studies (Sotiriou, Neo et al. 2003, Abd El-Rehim, Ball et al. 2005, Habashy,
Powe et al. 2012).
Luminal A.
Luminal A is the most common subtype of breast cancer and it accounts for 5060% of all breast cancer cases. It is characterized by expression of ER and/or PR, lack
of ERBB2 gene amplification and/or protein overexpression and lower levels of Ki-67 (a
marker for cell proliferation) (Carey, Perou et al. 2006, Yersal and Barutca 2014).
Moreover, they express cytokeratins 8 and 18, other markers including ER1, ER
function associated genes like LIV1 (zinc transporter ZIP6 or SLC39A6; solute carrier
family 39 zinc transporter, member 6), Forkhead Box A1 (FOXA1), X-box binding
protein 1 (XBP1), GATA binding protein 3 (GATA3), B cell lymphoma 2 (BCL2),
ERBB3 and ERBB4 (Carey 2010). This subtype has the best prognosis and has higher
survival rates and lower recurrence rates than other subtypes (Parise and Caggiano
2014, Shim, Kim et al. 2014).
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Anti-hormonal therapy is currently the standard treatment for women with
Luminal A breast cancer. Pre-menopausal women (18-49 years of age) are treated with
tamoxifen, a selective estrogen receptor modulator (SERM). Post-menopausal women
(50-85 years of age) are treated with aromatase inhibitors (anastrozole, letrozole or
exemestane) or tamoxifen (Swaby and Jordan 2008). Tamoxifen is a competitive
inhibitor of 17β-estradiol, the active form of estrogen. It binds directly to the ligand
binding domain of the ER and prevents binding of 17β-estradiol. Aromatase inhibitors
act by blocking aromatase-mediated synthesis of 17β-estradiol from androstenedione or
testosterone. The U.S. Food and Drug Administration (F.D.A.) has approved the use of
a selective estrogen receptor downregulator (SERD), fulvestrant for the treatment of
breast cancer in post-menopausal women that are diagnosed with advanced
(metastatic) hormone receptor positive breast cancer refractory to tamoxifen or
aromatase inhibitors.
Luminal B.
The luminal B subtype of breast cancer accounts for 15-20% of breast cancer
cases. This subtype has a poorer prognosis as compared to luminal- A due to higher
levels of Ki-67 and higher histological grade (Creighton 2012). Also, the luminal B
subtype has a higher recurrence rate and lower survival rates (Ellis, Tao et al. 2008).
Higher recurrence rates of luminal B breast cancers as compared to luminal A is limited
to first 5 years after the diagnosis (M. Ignatiadis 2009).
Luminal B breast cancer is characterized by expression of ER and/or PR, and
gene amplification and/or protein overexpression of HER2 in about 30% of cases (Loi,
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Sotiriou et al. 2009). The major contrast to the luminal A subtype is the increased
expression of proliferation-associated genes such as avian myeloblastosis viral
oncogene homolog (v-MYB), lysosome-associated transmembrane protein 4-beta
(LAPTMB4), gamma glutamyl hydrolase (GGH), nuclease sensitive element binding
protein 1 (NSEP1) and cyclin E1 (CCNE1) (Reis-Filho, Weigelt et al. 2010).
Advances in recent research have attributed the higher proliferation rate of
luminal B breast cancer to activation of growth factor pathways including fibroblast
growth factor receptor 1 (FGFR1), HER1, sarcoma proto-oncogene (Src) and
phosphoinositide 3 kinase (PI3K) catalytic alpha polypeptide (Tran and Bedard 2011).
If the tumor is non-metastatic, patients are treated with endocrine therapy along
with anti-HER2 therapy, depending on the HER2 status. The addition of chemotherapy
was found to be beneficial in patients with lower ER expression and a higher recurrence
score (as assessed by a 21-gene score referred to as OncotypeDX) (Albain, Barlow et
al. 2010)
Triple Negative.
The triple negative subtype of breast cancer accounts for nearly 15%-20% of all
breast cancer cases (Dawson, Provenzano et al. 2009). They do not express ER, or
PR, and lack gene amplification of ERBB2, hence, they are termed as triple negative.
Within triple negative breast cancer, there are numerous subtypes (Lehmann, Bauer et
al. 2011). The major subtype, basal-like breast cancer, express high levels of
myoepithelial basal markers including laminin and cytokeratins 5,14, and 17 (Nielsen,
Hsu et al. 2004, Cheang, Voduc et al. 2008). Also, basal-like breast cancer overexpress
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P-cadherin, fascin, caveolins 1 and 2, alpha-B crystallin and epidermal growth factor
receptor (EGFR)(Schneider, Winer et al. 2008). Basal-like cancer is associated with
frequent mutations of TP53 gene, inactivation of the retinoblastoma (Rb) pathway and
genomic instability. These tumors have a higher proliferative index, higher metastasis to
lung and brain, and demonstrate aggressive clinical behavior (Heitz, Harter et al. 2009).
It is important to note that although most triple negative breast cancers are basal-like,
they are other sub-categories including luminal, mesenchymal, stem-like, and androgen
receptor positive.(Lehmann, Bauer et al. 2011, Toft and Cryns 2011). Triple negative
breast cancer has the worst prognosis due to the lack of targeted therapy.
Chemotherapeutic agents have been traditionally used by oncologists for this subtype of
breast cancer. Since chemotherapeutic agents also affect rapidly dividing noncancerous cells, the patient experiences adverse effects such as alopecia, bone marrow
suppression and gastrointestinal disturbances(Chan and Giaccia 2008).
Based on immunohistochemistry and micro-array data, the basal-like subtype of
breast cancer accounts for about 75% of all BRCA1 mutant breast cancers. BRCA1 is
located on the long arm of chromosome 17(q21) and is a critical gene involved in the
repair of DNA damage. BRCA1 cancers are associated with a triple negative
phenotype, presence of high Ki-67, basal cytokeratins, TP53 mutations, EGFR, P
cadherin and X chromosome abnormalities. Just like women with basal-like cancer,
metastatic disease pattern and early relapse could be observed in cases of women with
BRCA1 cancers (Foulkes, Brunet et al. 2004). Clinical trials are underway for the
treatment of BRCA1 mutant breast cancer with poly ADP-ribose polymerase (PARP)
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inhibitor, which acts by completely shutting down the ability of the tumor cell to repair
the damaged DNA, thus resulting in accumulated damaged DNA, cell arrest in the G2/M
phase of the cell cycle, and apoptosis (Livraghi and Garber 2015).
Normal Breast-Like.
They comprise nearly 5-10% of all breast cancer cases. They are characterized
by the lack of ER/PR and HER2 expression. Because of this, they could be considered
as triple negative. However, they are not basal-like as they lack the expression of EGFR
and CK5. They show gene characteristics of adipose tissue and have an intermediate
prognosis between luminal and basal subtype of breast cancers. This is not a widelystudied subtype of breast cancer and its clinical significance remains unclear. No cases
of normal breast-like subtype were observed when microdissection was performed to
isolate tumor cells, supporting the notion of some researchers that this subtype might be
an artifact from contamination with normal tissue during microarrays (Weigelt, Mackay
et al. 2010, Yersal and Barutca 2014).
Human Epidermal Growth Factor Receptor 2 (HER2).
The HER2 positive subtype of breast cancer accounts for about 20% of all breast
cancer cases and is characterized by the gene amplification of ERBB2 located on
chromosome 17q12 and /or overexpression of its protein. The gene amplification is
detected by using fluorescence in-situ hybridization (FISH) and the protein
overexpression is detected by using immunohistochemistry (IHC) (Press, Finn et al.
2008). These tumors are highly proliferative (Peppercorn, Perou et al. 2008), more
aggressive (Slamon, Clark et al. 1987, Slamon, Godolphin et al. 1989), have early
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relapse and higher recurrence rates and harbor TP53 mutations in about 71% of the
cases (Peppercorn, Perou et al. 2008, Weigelt, Kreike et al. 2009). This subtype has
improved prognosis due to the availability of HER2 targeting agents (Slamon, LeylandJones et al. 2001).
HER2 or ErbB2 is a proto-oncogene which belongs to HER family of receptor
tyrosine kinase and was initially identified in a rat glioblastoma model. Other members
of the family include HER1/ErbB1 (EGFR), human epidermal growth factor receptor 3
(HER3)/ErbB3, and human epidermal growth factor receptor 4 (HER4)/ErbB4. HER
family of proteins are Type I growth factor receptor tyrosine kinases (RTKs) which
respond to extracellular growth factors to activate multiple signaling cascades. Their
structure consists of an extracellular ligand binding domain, a transmembrane domain,
and an intracellular tyrosine kinase domain (Citri, Skaria et al. 2003). Subdomains I (L1)
and III (L2) of the extracellular domain mediate ligand binding (Lax, Bellot et al. 1989,
Summerfield, Hudnall et al. 1996), whereas the cysteine-rich subdomains II (S1) and IV
(S2) are critical for receptor dimerization. There are 11 known ligands for the four HER
receptors. All the ligands possess an EGF-like domain and intramolecular loops
containing three disulfide bonds. This receptor-binding domain is a part of a large
precursor which also contains immunoglobulin-like domains, glycosylated linkers, and
heparin binding sites (Yarden and Sliwkowski 2001). The transmembrane region’s
expression and processing is tightly regulated. Some ligands that bind multiple
receptors have narrow specificity, whereas others bind to distinct receptors (Jones,
Akita et al. 1999). Table 1 depicts the ligands that bind to each receptor. HER3 receptor
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has a weak tyrosine kinase activity (Guy, Platko et al. 1994) and HER2 receptor has no
known ligand (Klapper, Glathe et al. 1999). Thus, by dimerizing with HER2, HER3 can
mediate distinct signaling pathways.
HER
Receptor
HER1

HER3
HER4

Ligands
Amphiregulin, Epidermal Growth Factor (EGF), Epigen, Epiregulin, βCellulin, Heparin-Binding EGF-like Growth Factor (HBEGF) and
Transforming Growth Factor – α
Neuregulin1 and Neuregulin2
Neuregulin1, Neureulin2, Neuregulin3, Neuregulin4, β-Cellulin,
HBEGF and Epiregulin

Table 1: Ligands for HER Family Receptors. (Shah and Osipo 2016).
The extracellular domain of the HER family of receptors can be in an open
confirmation or a closed confirmation. In the closed confirmation, the S1 and S2
subdomains of HER1, HER3 and HER4 interact with each other. Upon ligand binding in
the L1 and L2 subdomains of the receptor, there occurs a structural change which
protrudes the S1 dimerization loop and favors the open confirmation. HER2 exists in a
constitutively active confirmation and does not cycle between active and inactive states.
The HER2 receptor either homodimerizes or heterodimerizes with other HER receptor
(Citri, Skaria et al. 2003). Selection of the dimerizing HER partner is critical for the
signaling activity and a hierarchical pattern is followed, favoring heterodimer formation
over homodimer formation. Overexpression of a certain receptor can skew the
hierarchy. For example, ERBB2 gene amplification and thus HER2 protein
overexpression leads to more HER2 homodimer and heterodimer formation, depending
on expression of other HERs and their growth factors. HER2 has a strong catalytic
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kinase activity and hence HER2 heterodimers have strongest signaling functions. This
conclusion is based on the strong receptor transphosphorylation and mitogenesis
observed due to extensive interaction between HER2 and the ligand occupied EGFR,
HER3 and HER4 (Tzahar, Waterman et al. 1996). HER2-HER3 is the most active
signaling dimer, and is known to be critical for various developmental processes and
biological functions (Citri, Skaria et al. 2003, Moasser 2007).
Depending on the dimerization partners, both cis- and trans-phosphorylation of
tyrosine residues within their intracellular domains can lead to activation of the receptor
tyrosine kinase domain. Once activated, the receptor tyrosine kinase can lead to
docking of intracellular signaling molecules and downstream activation of PI3K/protein
kinase B (PKB)/Akt or mitogen-activated protein (MAP) kinase signaling cascade. When
HER2 dimerizes with HER3, HER2 trans-phosphorylates many tyrosine residues on
HER3. The result is recruitment of adaptor proteins that initiate PI3K or MAP kinase
signaling. Specifically, the p85 subunit of PI3K interacts with phosphorylated tyrosine
residues on HER3 at 6 consensus sites (Hellyer, Cheng et al. 1998). Upon docking with
HER3, the regulatory subunit, p85 interacts with the p110 catalytic subunit and activates
PI3-Kinase. Thus, HER3 drives HER2-mediated PI3K signaling. The signaling pathways
have been shown to promote cell survival, proliferation, motility, invasiveness,
resistance to apoptosis and angiogenesis. The output depends upon the cell context,
the ligand involved and the dimer formed (Yarden and Sliwkowski 2001, Citri, Skaria et
al. 2003, Linggi and Carpenter 2006, Moasser 2007, Dey, Williams et al. 2015). Figure 1
summarizes the HER signaling pathway.
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Drugs that are used to target HER2 include humanized, therapeutic monoclonal
antibodies, trastuzumab and pertuzumab, a dual EGFR-HER2 tyrosine kinase inhibitor,
lapatinib, trastuzumab coupled with a cytotoxic agent, emtansine (T-DM1) and taxane
based chemotherapeutic agents (Drakaki and Hurvitz 2015).
The two antigen specific sites of trastuzumab binds to the subdomain IV of the
HER2 transmembrane protein. This prevents the activation of the intracellular receptor
tyrosine kinase. There are several mechanisms by which trastuzumab inhibits HER2
signaling. These include – inhibition of HER2 dimerization, G1 cell cycle arrest
associated with induction of p27KIP1, inhibition of shedding of HER2 extracellular
domain, increased endocytic downregulation of HER2 receptor, inhibition of
angiogenesis, and antibody-dependent cell-mediated cytotoxicity (ADCC). Based on
previous clinical trials, trastuzumab was not effective as a monotherapy in metastatic,
HER2+ breast cancer, and the response rate ranged from 11-26% (Hudis 2007).
Pertuzumab is another therapeutic monoclonal antibody that prevents the dimerization
of HER2 with other HER receptors, primarily the formation of HER2-HER3 dimer. It acts
by binding the extracellular domain of HER2 at a different epitope than trastuzumab
(subdomain II). In the metastatic, HER2+ breast cancer setting, the combination of
trastuzumab plus pertuzumab in combination with docetaxel increased overall survival
by 15.7 months as compared to trastuzumab plus chemotherapy without pertuzumab in
the CLEOPATRA clinical trial, (Swain, Baselga et al. 2015), suggesting that the
combination therapy provides a more comprehensive blockade of HER2. As per the
American Society of Clinical Oncology (ASCO) guidelines, this remains the first line of
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treatment for patients with HER2+ breast cancer, unless the patient has severe heart
problems. It is used in neoadjuvant and metastatic settings. Along with HER2+, if the
tumor is hormone receptor positive, then hormonal therapy is included in the regimen
along with anti-HER2 therapy. Only in HER2+/ER+ indolent metastatic breast cancer,
hormonal therapy is prescribed along with anti-HER2 treatment.
T-DM1 is an antibody drug conjugate consisting of therapeutic humanized
monoclonal antibody trastuzumab linked to cytotoxic agent DM1 through a noncleavable linker. In the case of intrinsic resistance, or if tumor recurrence is observed
within 12 months, T-DM1 is used as a second line of treatment. The EMILIA clinical
study that was conducted in patients with locally advanced or metastatic HER2+ breast
cancer found that the progression free survival of patients that received T-DM1 was
significantly higher than the ones that received lapatinib plus capecitabine (Verma,
Miles et al. 2012). Lapatinib is approved along with capecitabine or other chemotherapy
and anti-HER2 combinations as the third line of treatment for advanced or metastatic
breast cancer patients that have previously received anthracycline, taxane or
trastuzumab (Geyer, Forster et al. 2006).
Despite the numerous advancement and efforts, the clinical challenge is that a
significant number of patients develop either intrinsic or acquired resistance to the
treatment. The tumor relapses in a more aggressive fashion, undergoes epithelial to
mesenchymal transition (EMT) that facilitates metastasis and evades HER2 targeting.
Hence, it is critical to understand the mechanisms of drug resistance and tumor
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recurrence for anti-HER2 agents, and develop novel therapeutic strategies to prevent
resistance.
HER2+ Breast Cancer: Drug Resistance
As mentioned previously, drug resistance to HER2 targeted agents is a major
challenge. Numerous pre-clinical and clinical research studies have been undertaken to
understand the mechanisms of intrinsic and acquired drug resistance. These
mechanisms include:
i. HER2 mutations.
ii. Co-expression of other receptors or crosstalk with other signaling pathways.
iii. Defects in apoptosis and cell cycle regulation.
iv. Involvement of host factors that modulate drug response.
Emerging clinical evidence supports the use of combination therapy targeting these
resistance mechanisms along with anti-HER2 therapy for more effective treatment of
patients suffering from HER2+ breast cancer (Rexer and Arteaga 2012).
HER2 Mutations.
Mutations in HER2 cause alterations in the binding of the drug to the target. A
truncated form of HER2 called p95-HER2 lacks the N-terminal extracellular region
including the antibody binding region. This form arises through alternate transcription
initiation sites in HER2 (Anido, Scaltriti et al. 2006), retains the kinase activity and hence
lapatinib is effective under these conditions, but not trastuzumab (Scaltriti, Rojo et al.
2007). Cell lines expressing the splice variant of HER2 – D16 HER2 lacks exon16 in the
extracellular domain and expression results in resistance to trastuzumab (Castiglioni,
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Tagliabue et al. 2006, Mitra, Brumlik et al. 2009). The variant acts by stabilizing the
homodimer and preventing its disruption by the antibody (Castiglioni, Tagliabue et al.
2006). Co-expresssion of HER2 with membrane associated glycoprotein mucin-4
(MUC4) can block the binding sites of trastuzumab (Price-Schiavi, Jepson et al. 2002,
Nagy, Friedlander et al. 2005). A cleaved form of MUC1 was overexpressed in a cell
line with trastuzumab resistance (Fessler, Wotkowicz et al. 2009). Moreover studies
have shown that the cleaved form can homodimerize and initiate the signaling cascade
for cell survival and proliferation (Hikita, Kosik et al. 2008, Mahanta, Fessler et al. 2008).
Activation of Compensatory Signal Transduction Pathways.
Receptor tyrosine kinases. HER2 can heterodimerize with other members of
the HER family and signaling initiated by the ligands of EGFR, HER3 and HER4 would
bypass the ligand independent effect of trastuzumab (Moulder, Yakes et al. 2001,
Motoyama, Hynes et al. 2002). Transactivation of HER2 by other RTKs could amplify
the signal transduction, and thus lapatinib and trastuzumab won’t be effective. An
acquired resistance model of trastuzumab in breast cancer xenografts has shown
increased expression of ligands for HER3 and EGFR, resulting in HER3 and EGFR
activation (Ritter, Perez-Torres et al. 2007). Increased availability of HER ligands is also
related with activation of transforming growth factor (TGF)-β receptors, which activate a
disintegrin and metalloprotease (ADAM) / tumor necrosis factor-alpha converting
enzyme (TACE) to release amphirelgulin, heregulin and TGF-α. These ligands activate
HER3. Expression of a constitutively active mutant form of TGF-β type I receptor results
in a gene signature that correlates with poor clinical outcome and trastuzumab
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resistance (Wang, Xiang et al. 2008). An increase in the insulin-like growth factor 1
receptor (IGF-1R) or signaling through IGF-1R/HER2 can lead to strong activation of
PI3K-Akt signaling and confer resistance to trastuzumab (Lu, Zi et al. 2001, Nahta,
Yuan et al. 2005). Lapatinib or a neutralizing antibody against IGF-1R was found to
overcome IGF-1R mediated trastuzumab resistance (Nahta, Yuan et al. 2005, Nahta,
Yuan et al. 2007, Browne, Crown et al. 2011).
Trastuzumab treatment has been shown to upregulate levels of cellular
mesenchymal to epithelial transition factor (c-MET), the hepatocyte growth factor
receptor. Overexpression of c-MET and its ligand, HGF was shown to confer
tratuzumab resistance in breast tumors from subset of patients that did not respond to
chemotherapy plus trastuzumab (Shattuck, Miller et al. 2008). Overexpression of ephrin
A2 receptor (EphA2) was associated with reduced disease free survival in patients and
conferred trastuzumab resistance in cell lines (Zhuang, Brantley-Sieders et al. 2010).
Erythropoietin receptor was found to be overexpressed in the cell lines that overexpress
HER2, and concomitant treatment of the cell lines with trastuzumab and erythropoietin
has been shown to confer resistance through janus kinase (Jak) and Src signaling. In
the metastatic setting, patients with HER2+ breast cancer treated with trastuzumab and
erythropoietin showed reduced progression free survival and overall survival (Liang,
Esteva et al. 2010).
The RTK, AXL was found to be upregulated in an acquired resistance model of
lapatinib. AXL was found to activate PI3K by engaging p85, and hence lapatinib and
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trastuzumab were not effective. Use of AXL inhibitor was found to restore the sensitivity
to anti-HER2 agents (Liu, Greger et al. 2009).
Intracellular kinases. Mutations in the PI3K/AKT signaling pathway have been
reported in about 30% of the invasive tumors. The PIK3CA gene encodes for the p110
catalytic subunit of PI3K, while the PIK3R1 gene encodes for the p85 regulatory
subunit. Gain of function mutations were identified in PIK3CA, AKT1 or PIK3R1 genes
which promote constitutive activation of PI3K. Also, loss of PTEN, a gene that encodes
a lipid phosphatase that reverses the PIP2 to PIP3 reaction mediated by PI3K has been
detected in many breast tumors. (Bellacosa, de Feo et al. 1995, Li, Yen et al. 1997,
Bachman, Argani et al. 2004, Carpten, Faber et al. 2007, Gewinner, Wang et al. 2009).
Since anti-HER2 agents act by inhibiting the PI3K signaling cascade, this gain of PI3K
mutations or loss of PTEN would lead to unregulated PI3K and resistance to anti-HER2
agents.
Loss of PTEN or presence of PIK3CA/PIK3R1 mutations conferred trastuzumab
resistance. Low levels of PTEN and presence of “hotspot” PIK3CA mutations were
associated with poor outcome observed in patients after trastuzumab plus
chemotherapy treatment (Berns, Horlings et al. 2007). The combination of trastuzumab
and a PI3K inhibitor, or trastuzumab or lapatinib with dual PI3K- mammalian target of
rapamycin (mTOR) inhibitor inhibited the growth of PIK3CA mutant-harboring breast
xenografts that were resistant to anti-HER2 therapy (Eichhorn, Gili et al. 2008, Serra,
Markman et al. 2008, Chakrabarty, Rexer et al. 2010) . Under conditions of PTEN loss,
the trastuzumab resistance was partially reversed by targeting AKT or mTOR (Lu,
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Wyszomierski et al. 2007). The strategy of targeting PI3K signaling cascade along with
HER2 has been tried clinically. BOLERO-I clinical trial evaluated the use of trastuzumab
along with the mTOR inhibitor, everolimus and paclitaxel as the first line of therapy for
patients with HER2 positive advanced breast cancer. However, no significant difference
was observed in progression free survival, even though there was prolongation of 7.2
months in the combination arm.
In case of acquired resistance to lapatinib, upregulation of Src family kinases
(SFK) was identified through mass spectrometry. Using an SFK inhibitor along with
lapatinib restored lapatinib sensitivity in a xenograft model and partially blocked PI3K
activation in resistant cells (Rexer, Ham et al. 2011). The combination of trastuzumab
and the Src inhibitor was able to overcome tarstuzumab resistance caused by D16
HER2 isoform and by PTEN’s inability to dephosphorylate Src (Mitra, Brumlik et al.
2009, Zhang, Huang et al. 2011). Trastuzumab resistance conferred by erythropoietin
receptor is mediated partly by Src, as the receptor activates Src thorugh Jak2 and Src
associates with HER2, phosphorylates PTEN and inactivates it (Liang, Esteva et al.
2010). Moreover, the EphA2 activation observed after chronic trastuzumab treatment
and during trastuzumab resistance is also mediated by Src (Zhuang, Brantley-Sieders
et al. 2010).
Defects in Apoptosis and Cell Cycle Control.
HER2 targeted therapies are known to arrest cell proliferation and induce
apoptosis. The levels of pro-apoptotic BH3-only Bcl2 family member BIM were reported
to be predictive of therapeutic response in HER2+ breast cancer. In that study, even
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though lapatinib inhibited HER2 and downstream signaling, apoptosis was only
observed in the cell lines that expressed higher levels of BIM, suggesting that BIM might
be a predictive biomarker for lapatinib response in an oncogene-addicted cancer
(Faber, Corcoran et al. 2011).
Survivin belongs to the inhibitor of apoptosis (IAP) protein family. It acts by
inhibiting caspases whose activity is critical for programmed cell death. Lapatinib
resistant HER2+ breast cancer cells show upregulation of ERα, which in turn causes
transcription of survivin through forkhead box O3 (FOXO3)a. Higher survivin levels
resulted in mediating lapatinib resistance (Xia, Bacus et al. 2006). Enhanced levels of
survivin and anti-apoptotic protein Mcl-1 were observed in trastuzumab resistant cells
(Valabrega, Capellero et al. 2011). Survivin levels are regulated in HER2+ amplified
breast cancer cell line by PI3K signaling, and inhibiting HER2-PI3K was shown to lower
the levels of survivin and cause apoptosis in HER2 overexpressing breast cancer cells
(Faber, Li et al. 2009, Tanizaki, Okamoto et al. 2011).
Alteration in the genes that are involved in the progression of cell cycle are also
known to play a role in mediating resistance to anti-HER2 therapy. Amplification of
cyclin E was associated with lower response to trastuzumab in HER2+ breast cancer,
and cyclin-dependent kinase 2 (CDK2) inhibitors were found to be effective against
trastuzumab-resistant xenografts (Scaltriti, Eichhorn et al. 2011). Downregulation of Cdk
inhibitor p27KIP1 is associated with trastuzumab resistance (Nahta, Takahashi et al.
2004) and the modulation of p27KIP1 level is the common endpoint for several resistance
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related pathways including signaling from IGF-1R and MET (Lu, Zi et al. 2001, Nahta,
Yuan et al. 2005, Shattuck, Miller et al. 2008).
Involvement of Host Factors that Modulate Drug Response.
ADCC is the killing of an antibody‐coated target cell by cytotoxic effector cells
through a nonphagocytic process, characterized by the release of the content of
cytotoxic granules or by the expression of cell death‐inducing molecules. Receptors for
the Fc region of Ig (FcR) on the plasma membrane of the effector cell are necessary for
ADCC activity (Teillaud 2012). Trastuzumab is known to cause ADCC. Natural killer
(NK) cells can target trastuzumab bound HER2 overexpressing cells through CD16
(FcγRIII)-mediated ADCC (Clynes, Towers et al. 2000). Host factors that affect the
immunomodulatory function can have an impact on trastuzumab resistance. Mice
lacking FcγRIII, and thus deficient in NK cells and macrophages binding to Fc region
showed reduced sensitivity to trastuzumab (Clynes, Towers et al. 2000). Polymorphism
in the human gene encoding FcgRIII is associated with trastuzumab response.
Leukocytes from patients who showed a better response to trastuzumab had higher
ADCC activity in-vitro, as compared to those who did not (Gennari, Menard et al. 2004).
A later study found that the quantity and activity of CD16(+) lymphocytes affect ADCC
induction by trastuzumab treatment, and thus the tumor response (Varchetta, Gibelli et
al. 2007).
Conclusion
Numerous mechanisms of de novo and acquired resistance to anti-HER2 agents
have been proposed in the pre-clinical and clinical settings. Emerging data suggest that
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targeting the HER2 signaling cascade at various points would lead to a more effective
therapy, rather than the use of single agents. An important challenge is trying to identify
the resistance mechanism in the individual patient to provide personalized therapy. In
order to achieve this, it would be important to perform biopsies of the primary and
metastasized tumors at regular intervals for pathological examination and molecular
analysis. Pre-operative therapy using the combination of anti-HER2 agents should
guide the treatment based on pathological response rate, and extensive molecular
profiling should be performed on the residual drug resistant tumors to identify better
treatment strategies. Furthermore, the crosstalk of HER2 signaling pathway with other
signaling pathways should be studied and novel biomarkers to predict drug response
and resistance should be identified.
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Figure 1: The HER Signaling Pathway.

CHAPTER II
CANCER STEM CELLS (CSCs) AND NOTCH SIGNALING: A LITERATURE REVIEW
The CSC Hypothesis
The drug resistance observed with the anti-HER2 agents could be explained by
the presence of CSCs or tumor initiating cells (TICs). Since their identification in 1994,
CSCs have received major attention in the field of cancer research, due to their ability to
initiate and drive tumor growth, cause radiation and chemotherapy resistance, and
promote tumor recurrence. The neoplastic subpopulation of CSCs is believed to
comprise a subpopulation of the heterogeneous tumor mass. CSCs are at the apex of
the hierarchy and possess the characteristics of self-renewal (yielding daughters that
remain as CSCs), slow proliferation, and the ability to differentiate into multiple lineages
of neoplastic cells that comprise the bulk of the tumor.
There are multiple theories regarding the origin of breast CSCs. According to
some, dysregulation or mutations within normal cells leads to their transformation into
CSCs. As per others, genetic modifications within the progenitor cells or normal stem
cells can give rise to CSCs (Pattabiraman and Weinberg 2014, Bozorgi, Khazaei et al.
2015, Shah and Osipo 2016). Because of this discrepancy regarding the origin of CSCs,
there is controversy in the field about the use of the term “CSCs”. Since the CSC fulfills
the criteria of a true stem cell – i.e. it gives rise to a metastatic lesion by undergoing
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self-renewal and recapitulating the entire tumor population, the nomenclature should
hold valid (Jordan 2009). Figure 2 summarizes the CSC hypothesis.
Proposed Markers to Identify Breast CSCs.
Breast CSCs have been isolated from human tumors as well as from pleural
effusions using flow cytometry. The cells were isolated based on expression of certain
surface proteins such as CD44+/CD24-/low/ESA+ (epithelial specific antigen). However,
they lacked the expression of specific lineage markers (Lin-). These cells showed
enhanced tumorigenic potential, as compared to bulk tumor cells when injected into
immune compromised mice. (Al-Hajj, Wicha et al. 2003). Since then, CD44+/CD24-/low
has been reliably used as a marker to isolate breast CSCs, and studies have reported
the enrichment of these markers in basal like cell lines and primary breast carcinomas.
CD44 is associated with stem cell characteristics and CD24 is related to differentiated
epithelial features. CD44 is a specific receptor to hyaluronan and a cell surface
glycoprotein. It is important for breast cancer adhesion, migration, and invasion. It is
also involved in angiogenesis and cell proliferation. CD24 is another glycoprotein and
when expressed at low levels, increases the ability of the tumor to grow and
metastasize (Ricardo, Vieira et al. 2011, Bozorgi, Khazaei et al. 2015).
The other widely used marker for the isolation of breast CSCs is aldehyde
dehydrogenase (ALDH), which is an enzyme involved in the oxidation of the aldehydes
to carboxylic acids, i.e. acetaldehyde to acetic acid or formaldehyde to formic acid using
NAD+ as a proton receptor. ALDH1A1 is the dominant form of the enzyme found in
mammals and is involved in the conversion of retinaldehyde to retinoic acid. Through in
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vitro and in vivo studies, Ginestier et al. showed that normal and cancer mammary
epithelial cells that have enhanced ALDH activity show stem/progenitor properties.
ALDH1A1+ CSCs are more resistant to platinum analogs, are more aggressive and
predict poor patient prognosis (Ginestier, Hur et al. 2007, Ricardo, Vieira et al. 2011,
Bozorgi, Khazaei et al. 2015).
Recently, cell lineage markers are used in tumor models to identify the hierarchy
of CSCs and various studies have demonstrated that heterogeneity exists between
CSC populations and that the cells have the capacity to interconvert between the stem
and non-stem states (Owens and Naylor 2013). Whether different markers identify the
same subpopulation or different remains unclear. Since CD44+/CD24-/low and ALDH are
the most widely studied markers for breast CSCs, a study was performed to study their
relative distribution within the intrinsic molecular subtypes. Four hundred and sixty-six
invasive breast carcinomas and eight breast cancer cell lines were used for the study.
Basal like tumors contained a higher percentage of cells with CD44+CD24−/low
expression. About 40% of ALDH positive cases were also basal-like. The study of
breast cancer cell lines showed that luminal cells were mainly CD44 −/lowCD24+, whereas
basal/mesenchymal cell lines were enriched for the CD44+CD24−/low phenotype. The
remaining basal/epithelial cell lines were positive for both markers. ALDH activity was
mainly observed in HER2 overexpressing basal/epithelial cell (Ricardo, Vieira et al.
2011). Recent work by Liu et al. suggests that ALDH is a better indicator for epithelial
like breast CSCs and CD44+CD24−/low is a better predictor of mesenchymal like CSCs.
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Epithelial like CSCs are more localized and they proliferate rapidly, whereas
mesenchymal like CSCs are more invasive and generally quiescent (Liu, Cong et al.
2014).
Besides these, there are other markers that have been used to identify breast
CSCs. BRCA1 mutant tumors contain CD44+/CD24-/CD133+ cells (Wright, Calcagno et
al. 2008) and ER negative breast CSCs possess CD44+ CD49fhi CD133/2hi phenotype
(Meyer, Fleming et al. 2010). CD49f was identified as a breast CSC marker in MCF7
cell line (Cariati, Naderi et al. 2008), and CD61 was recognized as a breast CSC marker
in certain mouse models of mammary tumorigenesis (Vaillant, Asselin-Labat et al.
2008). In a study performed using multiple breast cancer cell lines and primary tumors,
different markers were expressed by different cell lines, and the cells obtained from
primary tumors expressed varying amounts of different CSC markers. This suggests the
presence of multiple lineages of human breast cancer stem/progenitor cells present
within the heterogeneous breast tumor mass (Hwang-Verslues, Kuo et al. 2009).
In vitro propagation of human mammary stem/progenitor cells is studied by
culturing the cells as mammospheres in a 3D culture system. The assay could be used
for the quantification of stem cell activity and self-renewal of normal as well as cancer
cells. Each mammosphere is believed to arise from individual stem cell and the
quantification of the mammospheres gives an idea about the stem cell/ CSC frequency.
It is calculated as % mammosphere forming efficiency (%MFE) %MFE = (Number of mammospheres formed/Number of cells seeded)*100. To assess
the true self-renewal capacity, the primary mammospheres are disaggregated and
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replated into subsequent medium conditions. Subsequent formation of secondary and
tertiary mammosphere is evaluated and the result is indicative of the self-renewal
capacity of the original CSC. (Shaw, Harrison et al. 2012).
The In vivo study is performed by using a limiting dilution assay. It remains the gold
standard for the assessment of CSC frequency. The assay involves injecting SCID/NOD
mice with different log fold dilution of cells (For example: 10 cells,100 cells, 1000 cells,
10k cells) and assessing tumor take. Based on the tumor take observed at each dilution,
CSC frequency can be calculated using the extreme limiting dilution analysis (ELDA)
software. The self-renewal is measured in vivo by re-implanting the tumor and assessing
the tumor take (Hu and Smyth 2009).
HER2+ Breast CSCs.
The current work focuses primarily with breast CSCs from the HER2+ subtype of
breast cancer. “However, it is important to note that HER2 is selectively expressed in
HER2-, ER+ luminal breast CSCs and the HER2+ CSCs of HER2- breast cancer could
be targeted by employing anti-HER2 agents as listed before (Ithimakin, Day et al. 2013).
The HER2+ CD44 High/CD24 Low breast CSCs isolated from the HER2 negative
breast cancer cells showed enhanced ALDH activity, invasiveness
and in vivo tumorigenesis, as compared to HER2- breast CSCs (Duru, Fan et al. 2012).
HER2+ CSCs display a distinct genotype as compared to non-HER2+ CSCs
through altered epigenetic regulation. HER2 strongly regulates genes related to stem
cell and progenitor cell control (Rahmatpanah, Jia et al. 2012). Moreover, HER2+ CSCs
display elevated levels of genes that promote S to G2/M transition and reduced
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expression of genes that promote differentiation and immune response (Liu, Voisin et al.
2012, Shah and Osipo 2016).” The table below summarizes the distinctive features of
HER2+ CSCs versus non-HER2+ CSCsParameter
HER2 overexpression
Subtypes
Anti-HER2 agents
Phenotype

Genotype

HER2+ CSC
Observed
Luminal A, Luminal B and
HER2+
Effective for treatment
High ALDH activity,
mammosphere formation,
invasiveness, and
tumorigenesis, as
compared to Non-HER2+
CSC.
Higher self-renewal and
replicative potential.
Increased regulation of
genes related to stem cells
and progenitor cell control.
Increased expression of
genes related to S/G2/M
transition. Reduced
expression of genes
involved in differentiation
and immune response.

Non-HER2+ CSC
Not observed
All subtypes
Not effective for treatment
Low ALDH activity,
mammosphere formation,
invasiveness, and
tumorigenesis, as
compared to HER2+ CSC.
Lower self-renewal and
replicative potential, as
compared to HER2+ CSC.
Decreased regulation of
genes related to stem cells
and progenitor cell control,
decreased expression of
genes related to S/G2/M
transition. Increased
expression of genes
involved in differentiation
and immune response, as
compared to HER2+ CSC.

Table 2: HER2+ CSCs Versus Non-HER2+ CSCs. (Shah and Osipo 2016)
Numerous signaling pathways have been implicated in the formation of CSCs in
HER2+ breast cancer. These include developmentally conserved pathways like Notch,
Wnt, and Sonic Hedgehog signaling. Besides these, other signaling pathways such as
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), IL-8-CXCR
(Interleukin 8- CXC motif chemokine receptor), JAK/STAT (Janus kinase/signal

31

transducers and activators of transcription), TGF-β and PI3K-Akt signaling pathways
have been involved in the differentiation and the self-renewal of HER2+ breast CSCs
(Shah and Osipo 2016). The role of Notch signaling has been described in detail in the
later part of this chapter.
EMT and CSCs.
EMT is a phenomenon whereby the cells lose their differentiation characteristics
of cell-cell adhesion and migration and instead acquire mesenchymal traits resulting in
enhanced motility and invasion, and resistance to apoptosis. It is associated with the
loss of epithelial markers such as E-cadherin, and upregulation of mesenchymal
markers including N-cadherin, vimentin, and fibronectin. EMT was initially studied for its
importance during normal development. For neoplastic cells, EMT seems to confer a
distinct advantage that allows cells to disseminate to distant sites and initiate
metastases. EMT is known to be involved in the formation of breast CSCs (Mani, Guo et
al. 2008, Morel, Lievre et al. 2008). Following hormonal/chemotherapy, breast cancer
cells show an upregulation of a gene signature associated with EMT. This is indicative
of epithelial-mesenchymal plasticity in the development of drug resistance. The
surviving cells have gene determinants like breast CSCs and exhibit epithelial marker
cytokeratin and mesenchymal marker vimentin (Creighton, Li et al. 2009, Farmer,
Bonnefoi et al. 2009, Li, Xu et al. 2009, Creighton, Chang et al. 2010). EMT-related
signals are believed to arise from the stroma which then induces EMT-transcription
factors, whose expression results in the acquisition of mesenchymal traits. Based on the
transcription factor that is involved, the cells can enter a stem-like-cell state,
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mesenchymal-like state or both. Even though not reported, accumulating evidence
points to normal stem cells and CSCs arising in epithelial tissues with a mixture of
epithelial and mesenchymal characteristics, suggesting that they have partially
undergone EMT (Guo, Keckesova et al. 2012, Pattabiraman and Weinberg 2014). The
gene expression profile of the epithelial and mesenchymal breast CSCs was found to
be similar across various molecular subtypes of breast cancer and resembles that of
basal and luminal stem cells observed in normal breast. It is the plasticity of breast
CSCs that allow them to transition between EMT and mesenchymal to epithelial
transition (MET) states, and undergo migration, invasion, and metastases at distant
sites (Liu, Cong et al. 2014).
In contrast to the findings regarding the role of EMT in the formation of breast
CSCs, a recent report by Xie et al. describes that the tumor initiating capacity of breast
cancer cell lines is independent of the EMT status. In the study, they observed that the
induction of EMT resulted in CD44+/CD24−/low phenotype, enhanced cell proliferation,
migration, resistance to radiation and doxorubicin in breast cancer cell lines. The
observed traits were attenuated by MET. However, neither EMT or EMT affected the
tumor initiating capacity of the breast cancer cell lines, as measured by the limiting
dilution assay. (Xie, Ji et al. 2014).
CSCs and Tumor Microenvironment.
“The tumor microenvironment is the environment within which the tumor exists
and its constituents are cancer associated fibroblasts, leukocytes, mesenchymal stem
cells, lymphatic and blood endothelial cells, extracellular matrix and the signaling
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molecules. The tumor microenvironment is believed to provide a niche to CSCs which
helps them to thrive and maintain an immature phenotype. The microenvironment helps
the CSCs to evade the immune system and to undergo EMT and thus metastasize. The
microenvironment is responsible for the genetic changes and epigenetic variation.
CSCs activate or secrete various factors to maintain their survival. The tumor
microenvironment also plays a pivotal role in the regulation of bidirectional CSC and
non-CSC switch (Plaks, Kong et al. 2015). This could be possibly attributed to
EMT/MET plasticity that is exhibited by the tumor cells, to establish themselves in the
changing microenvironment at the primary and metastatic sites (Gao, Vahdat et al.
2012).
Tumor niche consists of a combination of cells that carry wild type HER2 and the
ones that harbor activating HER2 mutations in the tyrosine kinase domain. Recent work
by Wang et al demonstrates that the mutations impact the tumor microenvironment and
mediates the upregulation of growth factors such as Vascular Endothelial Growth Factor
(VEGF), TGF-β and EGFR ligands like amphiregulin and TGF-α. The secreted growth
factors promote autocrine and paracrine signaling which favors tumor growth (Wang, Yu
et al. 2010).
Cancer associated fibroblasts are known to mediate trastuzumab resistance in
HER2+ breast cancer through secretion of interleukin 6 (IL-6), expansion of CSCs and
by activation of multiple signaling pathways like NF-kB, JAK/STAT3 and PI3K/AKT
(Mao, Zhang et al. 2015).
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HER2 is selectively expressed in the CSCs of the HER2- subtype of breast
cancer and this involvement of HER2 is regulated by the tumor microenvironment.
HER2 expression is induced by Receptor Activator of Nuclear factor Kappa-B (RANK)
ligand produced by bone osteoblasts. Moreover, higher levels of HER2 are reported in
the bone metastatic setting as compared to the primary tumor and the circulating tumor
cells of HER2- breast cancer are known to express HER2. Currently, clinical trials are
underway to evaluate the efficacy of using a RANK ligand inhibitor denosumab along
with adjuvant therapy for the prevention of recurrence in the bone or any other part, in
women with early stage breast cancer who are prone to recurrence (Korkaya and Wicha
2013, Shah and Osipo 2016).”
Notch Signaling: A Literature Review
Introduction.
Notch signaling pathway was first discovered in 1914 through a genetic mutation
screen in Drosophila melanogaster (Dexter 1914). Soon after that, the mutant alleles
were identified and the flies that were affected showed a “notched” winged margin that
was passed on from parent to progeny (Morgan 1917). The Notch signaling functions in
a contact dependent fashion and it acts as a mediator of cell-cell communication. The
signals relayed through the pathway are found to be critical in various cellular processes
such as determining cell fates, promoting differentiation programs during development
and during maintenance of self-renewing adult tissues by stem/progenitor cell
maintenance, and, regulating cell death and cell proliferation. As Notch signaling
impacts cellular processes in a wide variety of tissues, aberrant gain or loss of signaling
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through its components has been implicated in numerous developmental disorders as
well as adult diseases (Kopan and Ilagan 2009).
Notch Signaling Pathway.
Notch signaling works in a contact dependent fashion to mediate the cell-cell
communication. The Notch ligand present on the signal sending cell engages with the
Notch receptor present on the signal receiving cell. There are five known Notch ligands
in mammals – Jagged1, Jagged2, Delta-like ligand-1 (DLL1), DLL3 and DLL4, and there
are four known Notch receptors – Notch1, Notch2, Notch3, and Notch4.
Notch receptors. While the fly has only one Notch receptor, and worms have
two redundant Notch receptors, the four mammalian Notch receptors can play a
redundant as well as unique roles. The extracellular domain of the Notch receptors
comprises of 29-36 tandem EGF repeats, some of which mediate ligand interaction.
Activating interaction with the ligand present on the neighboring cell (trans-activation) is
mediated by repeats 11-12, whereas inhibitory interaction (cis-inhibition) with the ligand
present on the same cell is mediated by repeats 24-29. Notch mediated lateral inhibition
regulates binary cell fate choice by activating Notch signaling in the neighboring cells in
the trans fashion and by preventing Notch signaling in the cis fashion if the ligand and
receptor are co-expressed on the same cell. Lateral inhibition is found to be important
during development and it plays a critical role in specifying differentiated cells from a
sheet of undifferentiated cells in a spatially regulated manner (Artavanis-Tsakonas,
Rand et al. 1999). The negative regulatory region (NRR) that prevents the receptor
activation in the absence of ligand binding, is followed by the EGF repeats. The NRR
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consists of three cysteine-rich Lin12-Notch repeats and a heterodimerization domain.
Cleavage of the Notch receptor by furin like convertase S1 results in the formation of
Notch extracellular domain-Notch transmembrane and intracellular domain (NECDNTMIC) heterodimer held together by non-covalent interactions (Ca2+) between the Nand C-terminal halves of the heterodimerization domain. The transmembrane domain is
followed by 3-4 Arg/Lys residues that provide the stop signal. The Notch intracellular
domain comprises the RBPjκ association module (RAM) domain, a long unstructured
linker containing nuclear localization signal (NLS) that links the RAM domain with the
seven ankyrin repeats (ANK domain), an additional bipartite NLS, a transcriptional
activator domain (TAD) and the PEST domain (proline-, glutamate-, serine-, threoninerich motifs), which is critical in maintaining the stability of notch intracellular domain
(NICD) (Kopan and Ilagan 2009). While Notch1 has a strong TAD, Notch2 has a weak
TAD (Radtke and Raj 2003). Notch3 and Notch4 lack a TAD. Notch4 is the least
conserved Notch receptor, having short extracellular and intracellular domains (Wu and
Bresnick 2007). Figure 3 shows the domain organization of Notch receptors and DSL
ligands.
Notch ligands. The Notch ligands are single-pass type I transmembrane
proteins characterized by three structural motifs: an N-terminal DSL (Delta/Serrate/LAG2) motif, specialized tandem EGF repeats called the DOS domain (Delta and OSM-11like proteins, and EGF-like repeats (both calcium binding and non-calcium binding)).
Both DSL and DOS domains are involved in receptor binding (Komatsu, Chao et al.
2008). The N terminal domain is conserved amongst the ligands, and can be subdivided
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into two regions – N1 which is cysteine-rich and N2 which is cysteine-free(Parks, Stout
et al. 2006). The Jagged ligands are longer than the Delta like ligands, the length
determined by the 6-16 EGF repeats present in the extracellular domain. Each EGF
repeat contains 6 cysteine residues, which form disulfide bridges facilitating protein
stabilization (Komatsu, Chao et al. 2008). A cysteine-rich region is located at the end of
EGF repeats, with Jagged ligands having an extra cysteine-rich region (Vitt, Hsu et al.
2001). Jagged ligands and DLL1 contains a DOS domain, whereas DLL3 and DLL4
don’t (Komatsu, Chao et al. 2008). The intracellular domain exhibits the lowest
homology among different ligands, and it consists of a shorter cytoplasmic tail than the
extracellular domain. Except for DLL3, all the ligands contain multiple lysine residues,
which are the sites of modification by the E3 ubiquitin ligases. Most DSL ligands have a
PDZ (postsynaptic density protein [PSD95], Drosophila disc large tumor suppressor
[Dlg1], and zonula occludens-1 protein [zo-1])-binding motif which aids in intracellular
protein–protein interactions (Pintar, De Biasio et al. 2007).
Jagged1. JAGGED1 (JAG1) is located on chromosome 20 at cytogenetic
location 20p12.2 and genomic location (GRCh37) chr20:10,618,331–10,654,693. It has
26 exons and it spans over 36kb. The protein contains 1218 amino acids (Oda,
Elkahloun et al. 1997). The 21-amino acid signal peptide present in the N-terminal
region of Jagged1 ensures its localization into the membrane. The EGF repeats 1 and 2
of Jagged1 are primarily important for increasing the affinity of Jagged1 with the Notch
receptors (Chillakuri, Sheppard et al. 2012). In humans, JAG1 expression varies during
development and amongst different tissues. In the adult, JAG1 is highly expressed in
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the heart, placenta, pancreas and prostate with lower levels found in lung, liver, kidney,
thymus, testis and leucocytes (Jones, Clement-Jones et al. 2000, Gasperowicz and
Otto 2008). A higher level of JAG1 mRNA and protein is associated with poor overall
survival of women with breast cancer (Reedijk, Odorcic et al. 2005, Dickson, Mulligan et
al. 2007). IL-6, Notch3, and β-catenin are known to promote transcriptional activation of
Jagged1 (Sansone, Storci et al. 2007, Rodilla, Villanueva et al. 2009, Chen, Stoeck et
al. 2010). Also, Rac1 is known to facilitate STAT3 mediated Jagged1 transcription.
(Zhao, Du et al. 2016)
Canonical Notch Signaling Pathway.
Canonical Notch signaling involves activation of the Notch receptor present on
the signal receiving cell through engagement with the DSL ligand present on the signal
sending cell. The Notch receptor is initially synthesized as a 300 kDa precursor in the
endoplasmic reticulum and cleaved into two subunits in the trans-Golgi compartment,
which is then cleaved by furin like convertase(s) through S1 cleavage. This cleavage
results into a heterodimer consisting of an extracellular N-terminal fragment and a
transmembrane plus intracellular domain C-terminal fragment, linked together by a noncovalent linkage. During the synthesis and trafficking of Notch receptors, the
extracellular portion of the receptor undergoes extensive N and O-linked glycosylation,
which is critical for the proper folding of the receptor, and its subsequent interactions
with the ligands. Glycosylation of Notch by Fringe glycosyltransferase enhances the
affinity of the Notch receptor for Delta ligands but reduces its affinity for Jagged ligands.
The three Fringe proteins expressed in mammals include- Lunatic fringe, Manic fringe
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and Radical fringe (Fortini 2009). Binding of the Notch receptor with the Notch ligand
results in an E3 ubiquitin ligase (Neuralized 1/2 or Mindbomb1/2) mediated endocytosis
of the ligand via mono-ubiquitylation, which provides the necessary pulling force to
expose the ADAM10/TACE/kuz/SUP-17 cleavage site present in the extracellular
portion of the transmembrane Notch C-terminal fragment. The S2 cleavage results in
ectodomain shedding of the extracellular portion of the transmembrane portion of the
Notch receptor at approximately 12 amino acids outside the transmembrane domain
(Brou, Logeat et al. 2000, Mumm and Kopan 2000). This leads to the formation of the
carboxyterminal fragment called Notch extracellular truncation (NEXT) (Reiss and Saftig
2009). The ligand and the extracellular portion of the Notch receptor is endocytosed into
the signal sending cell, where it undergoes endosomal degradation or recycling. NEXT
subsequently undergoes S3 and S4 cleavages by the aspartyl protease complex-γsecretase, which leads the formation of NICD (Mumm, Schroeter et al. 2000). The γsecretase complex consists of a catalytic subunit designated presenilin 1 or presenilin 2,
a seven-pass transmembrane protein, and accessory subunits comprised of the
transmembrane proteins nicastrin, anterior pharynx-defective 1 (APH1), and presenilin
enhancer 2 (PEN-2), a two-pass transmembrane protein. PEN-2 is stabilized by
nicastrin and APH1, and it mediates endoproteolysis of presenilin. The cleavage can
occur at the cell surface or within the endosomal trafficking (Lai 2002). In the absence of
NICD, the Notch target genes are repressed by the formation of the complex between
CSL (C promoter binding factor-1 [CBF-1], suppressor of hairless, Lag-1) family of
transcription factors and co-repressors. When the NICD translocates to the nucleus,

40

the ankyrin-repeat motif of NICD docks with the Rel homology region of the DNAbinding factor CSL and forms a transcriptional activation complex. This leads to removal
of co-repressors such as class I or II histone deacetylases, CBF-1-interacting repressor
(CIR), SKI-interacting protein (SKIP), silencing mediator of retinoid and thyroid hormone
receptor (SMRT), and SMRT/HDAC (histone deacetylase)-1-associated repressor
protein (SHARP), and a recruitment of transcription factor co-activators (CoAs) such as
mastermind-like 1–3 (MAML) protein. MAML further recruits the histone
acetyltransferases, cyclic AMP (adenosine monophosphate) response element binding
(CREB) protein CBP/p300 and p300/CBP-associated factor or general control nondepressible 5 (GCN5), which then leads to histone acetylation, unraveling of the DNA
wrapped around the histones, and active transcription of Notch target genes like hairy
and enhancer of split basic helix-loop-helix HES 1-7, HEY 1, 2, and HEY-L family of
proteins (transcriptional repressors), Deltex 1-4, cyclinD1, c-Myc, p21, and antiapoptotic Bcl-2 (Schroeter, Kisslinger et al. 1998).
Sustained Notch activation could be deleterious. Hence, it is critical to tightly
regulate the NICD turnover to prevent sustained signaling for a very long period or at
excessively high levels. NICD, during the process of transcriptional activation, is
phosphorylated on its PEST domain by cyclin C cyclin-dependent kinase-8 complex
(Cyc: CDK8) and glycogen synthase kinase 3β (GSK-3β) and is targeted by E3 ubiquitin
ligase Sel10/Fbw7 for proteasome-mediated degradation. This results in the
disassembly of the CSL/NICD/MAML ternary complex, allows the cell to become ligandcompetent and resets the signaling for a new cycle of activation (Wu, Lyapina et al.
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2001). Numb is a negative regulator of Notch signaling, and about 50% of breast
cancers lose Numb mediated control of Notch signaling, due to ubiquitylation and
proteasomal degradation of Numb (Pece, Serresi et al. 2004). Figure 4 provides an
overview of the Notch signaling pathway.
Notch Signaling in Mammary Gland Development.
Adult stem cells are important for organ development and for tissue homeostasis.
A single mouse mammary stem cell has been shown to reconstitute the entire
mammary gland (Shackleton, Vaillant et al. 2006). The recent identification of the
progenitor population proves that mammary epithelium comprises of stem cells which
give rise to differentiated epithelium through lineage restricted intermediates (Stingl,
Eaves et al. 2001, Sleeman, Kendrick et al. 2006, Asselin-Labat, Sutherland et al. 2007,
Villadsen, Fridriksdottir et al. 2007). The mammary gland comprises of ductal and
alveolar epithelial cells, and myoepithelial cells. Extracellular signals from cytokines and
hormones are presumed to control mammary stem cell activity and their progressive
lineage differentiation through specific regulatory pathways (Hennighausen and
Robinson 2001).
Several signaling pathways involved in cell fate and cell differentiation decisions
and stem cell maintenance are critical for the development of mammary gland. Notch
signaling is involved in several cell-fate decisions that occur through ligand-receptor
interactions. Activation of the receptor by a Notch ligand can lead to the specific fate of
a cell, whereas the absence of activation leads to an alternate fate (ArtavanisTsakonas, Matsuno et al. 1995).
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The Notch receptors, ligands, and the target genes are implicated in various
stages of mammary gland development. Notch signaling can play an important role in
mammary gland development by acting on stem cells as well as progenitor cells,
affecting their self-renewal and lineage specific differentiation (Dontu, Jackson et al.
2004). The steady state levels of Notch3, Jagged1, DLL3, and Hey2 mRNA were found
to be high during various stages of postnatal mammary gland development (Raafat,
Goldhar et al. 2011). During pregnancy, canonical Notch signaling regulates alveolar
cell maintenance and basal cell proliferation (Buono, Robinson et al. 2006). The Notch1
receptor is found to be expressed in the luminal compartment and its ectopic expression
in the basal compartment induces luminal cell commitment (Bouras, Pal et al. 2008).
During embryonic development, Notch-1 expressing cells are multipotent and can
produce all mammary lineages, whereas postnatally they exclusively maintain ERα
negative lineage. The ERα negative lineage possesses high self-renewal capacity, as
demonstrated by the ability of Notch-1 expressing cells to form the complete mammary
gland comprising of myoepithelial and luminal cells (Rodilla, Dasti et al. 2015). Notch3
activation was found to be critical for the restriction of bipotent progenitors to luminal cell
fate commitment, and this role of Notch3 was found to be non-redundant. In contrast to
the role of Notch3, Notch4 gene expression is highest in the undifferentiated mammary
progenitors, whereas the expression is downregulated when the cells become
committed to luminal lineage (Raouf, Zhao et al. 2008). Constitutive activation of Notch4
in vitro inhibits differentiation of normal breast epithelial cells (Uyttendaele, Soriano et
al. 1998). In vivo, the constitutively active form of Notch4 results in a failure to develop
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normal mammary gland, and subsequently develops mammary tumors (Soriano,
Uyttendaele et al. 2000).
Thus, various components of the Notch signaling cascade are involved in normal
mammary development, and its aberrant activation can lead to breast cancer by
deregulating the self-renewal of normal mammary stem cells.
Notch Signaling in Cancer.
Involvement of Notch signaling in human cancer was first demonstrated in T cell
acute lymphoblastic leukemia (T-ALL) in 1991, where Notch1 was associated with
chromosomal translocation (Ellisen, Bird et al. 1991). It was later observed that most TALL cases were associated with mutations in Notch1, resulting in ligand-independent
proteolytic cleavage of Notch1, an increased stability of NICD, resulting in constitutive
activation of Notch signaling. Unlike in T-ALL, mutations are not frequently observed in
Notch genes in solid tumors. However, aberrant activation of Notch signaling has been
reported in solid tumors, which can occur due to loss of negative regulators, such as
Numb, or due to altered expression of Notch receptors and ligands, as observed in
prostate cancer, colorectal cancer, glioblastoma, cervical cancer, pancreatic cancer,
renal cell carcinoma and breast cancer (Ranganathan, Weaver et al. 2011, OlsauskasKuprys, Zlobin et al. 2013). Interestingly, the tumor suppressor role of Notch signaling
has been noted in mouse keratinocytes, hepatocellular and pancreatic carcinoma, and
in small cell lung cancer (Koch and Radtke 2007). This dual role of Notch signaling
could be explained by the crosstalk of Notch signaling with other pathways, the stage of
cancer progression and the role of the tumor microenvironment.
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Notch Signaling and Breast Cancer.
Many components of the Notch signaling pathway were found to be elevated in
invasive breast cancer, including DLL1,3,4, Jagged1-2, Notch receptors, HES and HEY
gene transcripts (Mittal, Subramanyam et al. 2009). Enhanced co-expression of
Jagged1 and Notch1 has been linked with poor prognosis in breast cancer (Reedijk,
Odorcic et al. 2005, Dickson, Mulligan et al. 2007). Moreover, Numb, the negative
regulator(Zhang, Wang et al. 2010) of Notch has been found to be lost in about 50% of
breast cancers through ubiquitylation and proteasome-mediated degradation (Pece,
Serresi et al. 2004). Notch signaling has been shown to be activated in ER+ and HER2+
breast cancer following drug treatment (Osipo, Patel et al. 2008, Rizzo, Miao et al.
2008). Triple negative breast cancers were found to be enriched with activating
mutations within the PEST domain of Notch1, Notch2 and Notch3(Wang, Zhang et al.
2015). Conditional deletion of Lunatic Fringe in the mammary gland led to Jagged1
mediated Notch signaling and formation of basal like mammary tumors (Xu, Usary et al.
2012).
The role of Notch receptors in breast cancer is evident from the in vivo studies
performed using murine transgenic models. Overexpression of Notch1 NICD and
Notch3 NICD mediated by the mouse mammary tumor virus (MMTV) transgenic mice
led to inhibition of mammary gland development and induction of mammary tumors (Hu,
Dievart et al. 2006). MMTV insertion in the NOTCH1 gene led to overexpression of
mutant Notch protein, which was capable of transforming HC11 mouse mammary
epithelial cells in vitro and generating spontaneous tumors in vivo (Dievart, Beaulieu et
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al. 1999). Notch1 was also found to be a mediator of oncogenic Ras signaling. Mutated
Ras plays a central role in breast oncogenesis (Weijzen, Rizzo et al. 2002). Notch3
knockdown reduced osteoblast and TGF-β1 stimulated colony formation in breast
cancer cells. Moreover, osteolytic lesions were reduced upon inoculation of cells with
reduced Notch3 expression, suggesting that Notch3 plays a critical role in breast cancer
derived bone metastasis (Zhang, Wang et al. 2010).
Furthermore, Notch4 NICD, when expressed under whey acidic promoter (WAP)
or under MMTV promoter led to the formation of mammary tumors in mice.(Gallahan,
Jhappan et al. 1996, Gallahan and Callahan 1997). Transgenic expression of 1.8 kb
Notch4 RNA in non-malignant human mammary epithelial cell line MCF10A enabled the
cells to grow in soft agar, indicating the transformative potential of Notch4 (Imatani and
Callahan 2000). Moreover, Notch4 was found to promote the invasion of the
extracellular matrix and enhance the tumorigenic potential of mammary epithelial cells
in vitro (Soriano, Uyttendaele et al. 2000, Callahan and Raafat 2001).
Contrary to the role of other Notch receptors, Notch2 expression was found to be
associated with better survival in breast cancer patients, with high expression related
with well-differentiated and poorly proliferative tumors(Parr, Watkins et al. 2004).
Moreover, constitutively active Notch2 NICD led to increased apoptosis in MDA-MB-231
cells. Moreover, Notch2 NICD suppressed tumor take and growth in the MDA-MB-231
xenograft model, suggesting that Notch2 signaling is a potent inhibitory signal in breast
cancer (O'Neill, Urs et al. 2007).
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Notch Signaling and Breast CSCs.
The Notch signaling pathway is the most extensively studied in relation to CSCs.
And several Notch inhibitors are being developed for investigation. Notch signaling has
been implicated in the self-renewal of CSCs in various malignancies and in the tumorstroma and tumor-endothelium interactions in CSC niches in primary and metastatic
tumors (Pannuti, Foreman et al. 2010, Gu, Rizzo et al. 2012). Increased Notch1 NICD
accumulation and HES1 expression were observed in ductal carcinoma in situ as
compared to the normal mammary tissue (Farnie, Clarke et al. 2007). Breast CSCs
have enhanced Notch activation as compared to the bulk tumor cells, and inhibition of
Notch signaling reduces breast CSCs and prevents mammosphere formation
(Grudzien, Lo et al. 2010). Notch1 and Notch4 receptors were found to be differentially
expressed in breast CSCs and differentiated cells. Notch1 signaling was found to be
important in the activation of HER2, and thus HER2 mediated CSCs (Magnifico, Albano
et al. 2009). Robert Clarke and his colleagues reported that the breast CSC activity is
preferentially dependent on Notch4, rather than Notch1, and that Notch4 is required for
tumor initiation. They observed that pharmacologic or genetic inhibition of Notch1 or
Notch4 reduced CSC activity in vitro and tumor formation in vivo. However, Notch4
inhibition had a more pronounced effect and caused complete inhibition of tumor
formation in vivo. They propose a model whereby Notch4 regulates exit of BCSCs into
the proliferating progenitor population, whereas Notch1 activity regulates progenitor
proliferation and luminal differentiation (Harrison, Farnie et al. 2010). Notch3/Jagged1
were found to be involved in the CSC self-renewal and survival under hypoxic
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conditions (Sansone, Storci et al. 2007). Recently, it has been reported that de novo
and acquired resistance to anti-estrogens is driven by the Jagged1-Notch4 axis
dependent breast CSC activity (Simoes, O'Brien et al. 2015).
Crosstalk of Notch Signaling With Other Signaling Pathways in Breast
Cancer.
Notch signaling is important for cell proliferation, differentiation, cell survival,
vasculogenesis, and angiogenesis. Notch expression is regulated by hypoxia and
inflammatory cytokines like leptin, IL-6, and IL-8. Notch signaling is known to crosstalk
with developmentally conserved Hedgehog and Wnt signaling pathways, with growth
factors related signaling pathways including HER2/RTK signaling, platelet derived
growth factor (PDGF)/ platelet derived growth factor receptor (PDGFR) signaling, TGF-β
signaling and VEGF/ vascular endothelial growth factor receptor (VEGFR) signaling.
Moreover, janus kinase/signal transducers and activators of transcription (Jak/STAT)
signaling, Ras signaling, PI-3K/Akt signaling, mTOR signaling, nuclear factor-κB (NFκB) signaling, hypoxia inducible factor (HIF) signaling, ER signaling as well as various
micro-RNAs are known to crosstalk with Notch signaling pathway (Guo, Liu et al. 2011).
We are going to focus on the crosstalk of Notch signaling with HER2 signaling, ER
signaling, and polyoma enhancer activator 3 (PEA3). It is vital to identify the crosstalk of
Notch signaling with other pathways critical for breast cancer, as it will allow the
identification of novel biomarkers and lead to the development of better combinatorial
therapies that would be more effective in preventing drug resistance and tumor
recurrence.

48

Crosstalk between Notch1 and HER2 has been elucidated by our group and
various others since. Low Notch activity was observed in HER2 overexpressing breast
cancer cell lines. HER2 inhibition in the cells that were sensitive to trastuzumab resulted
in an increase in Notch1 activity and trastuzumab resistant cells were found to express
higher Notch1 and endogenous Notch1 targets. Treatment of trastuzumab sensitive or
resistant cells with a gamma-secretase inhibitor (GSI) plus trastuzumab or Notch1 small
interfering RNA (siRNA) resulted in a decrease in cell proliferation and an increase in
apoptosis, suggesting that increased activation of Notch1 followed by anti-HER2
therapy might be responsible for survival and drug resistance (Osipo, Patel et al. 2008).
In an in vivo model, we have shown that the Notch activation resulting from HER2
inhibition is responsible for tumor recurrence and that the combination of GSI and
trastuzumab prevents tumor recurrence (Pandya, Meeke et al. 2011). A recent report
found that Notch signaling is upregulated in tumor cells following HER2 inhibition, that
Notch signaling remains activated in a subset of dormant tumor cells that survive after
HER2 inhibition, that activation of Notch signaling accelerates tumor recurrence, and
that Notch inhibition impairs tumor recurrence (Abravanel, Belka et al. 2015).
In contrast to this, Chen et al. have shown that Notch signaling could regulate
HER2 expression as the HER2 promoter contains CSL binding sequences (Chen,
Fischer et al. 1997). Another group has shown that downregulation of Notch1 by siRNA
didn’t affect cell proliferation of HER2+ breast cancer cell lines (Yamaguchi, Oyama et
al. 2008). Magnifico et al. demonstrated that HER2 overexpressing cells have active
Notch1 and that inhibition of Notch1 by siRNA or by GSI resulted in a decrease in
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mammosphere formation and downregulation of HER2 expression. These studies
reveal the importance of crosstalk between HER2 and Notch signaling and the need to
investigate this crosstalk in more detail.
Crosstalk between Notch and ER was described by Rizzo et al. They found that
in ERα+ breast cancer cells, 17 beta-estradiol inhibits Notch1 NICD levels, reduces
notch activity and affects the cellular distribution of Notch1. Inhibition of ERα by
tamoxifen or raloxifene resulted in reactivation of Notch activity. Notch1 induced Notch4.
In clinical specimens, they observed that Notch4 expression correlated with higher
levels of Ki-67, and thus cell proliferation. The combination of GSI and tamoxifen was
found to be more effective in the regression of T47D: A18 induced xenograft tumors,
indicating that the combination of Notch inhibitors and the anti-estrogens may be more
effective in the treatment of ERα+ breast cancers (Rizzo, Miao et al. 2008). Another
study revealed that Notch1 can activate ERα dependent transcription through IKKα in
breast cancer cells, suggesting the possibility of a feedback loop controlling the NotchERα crosstalk (Hao, Rizzo et al. 2010). A recent report reveals that the treatment with
antiestrogens results in the enrichment of breast CSCs through Jagged1-Notch4
activation mechanism in xenograft PDX tumors and patient-derived samples. The study
suggests that the combination therapy involving antiestrogens along with Jagged1Notch4 inhibition will be more beneficial in overcoming anti-estrogen resistance in
human breast cancers (Simoes, O'Brien et al. 2015). Overall, the crosstalk between
Notch and the ERα signaling pathway has a significant role in human breast tumor
biology and importantly resistance to anti-estrogens.
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For the triple negative subtype of breast cancer, PEA3, an Ets family
transcription factor, has been shown to activate the transcription of Notch1 and Notch4.
While PEA3 recruitment on the Notch-1 promoter was independent of AP-1 activity,
PEA3 recruitment to the Notch-4 promoter was dependent on AP-1 activity: positively
regulated by c-JUN and Fra-1 and negatively regulated by c-Fos. Combination therapy
targeting PEA3 and Notch was shown to be beneficial for the treatment of a more
aggressive triple negative subtype of breast cancer (Clementz, Rogowski et al. 2011).
Conclusion
CSCs have been implicated in drug resistance, radiation resistance, metastasis
and tumor recurrence. They’re identified in several solid tumors, including breast
cancer. They have been shown to promote self-renewal, give rise to progeny that is
different from them, and utilize various signaling pathways. There have been reports
regarding the plasticity of CSCs and non-CSCs, suggesting that it would be critical to
develop a combinatorial regimen that targets both CSCs and non-CSCs. This
combinatorial approach would be critical for the complete elimination of tumor, and for
the improvement of survival and quality of life of cancer patients.
In the context of HER2+ breast cancer, our group has identified a novel crosstalk
between HER2 and Notch signaling. We have found that HER2 restricts Notch
activation and that inhibiting HER2 by using anti-HER2 agents results in an increase in
Notch activation, drug resistance, and tumor recurrence. Another study revealed that
Notch signaling remains active in a subset of dormant tumor cells following HER2
inhibition, that the Notch activation is responsible for tumor recurrence, and that
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inhibition of Notch signaling impairs tumor recurrence. Together, these studies support
a role for Notch signaling in the formation of CSCs in HER2+ breast cancer. There have
been reports about the involvement of Notch1 and Notch4 receptors in the formation of
CSCs in HER2+ breast cancer. In the current study, we intend to identify the
mechanism by which Notch signaling leads to the formation of CSCs in HER2+ breast
cancer. This would help in the identification of the novel biomarkers and in the
development of newer drug targets for the inhibition of Notch signaling.
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Figure 2: The CSC Hypothesis.
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Figure 3: Domain Organization of Notch Receptors and DSL Ligands.
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Figure 4: The Notch Signaling Pathway.

CHAPTER III
MATERIALS AND METHODS
Cell Culture
HCC1954, MDA-MB-453 and MCF7 cells were purchased from American Type Culture
Collection (Manassas, VA). HCC1954 and MDA-MB-453 are HER2+ breast cancer cell
lines. MCF7 is a luminal A subtype cell line and it lacks HER2 overexpression. MCF7
cells overexpressing HER2, designated as MCF7-HER2, were generously gifted by Dr.
Mien-Chie Hung from The University of Texas MD Anderson Cancer Center in Houston,
Texas. HCC1954 and MDA-MB-453 cells were grown in Dulbecco's Modified Eagle
Medium (DMEM, Thermo Fischer Scientific, Waltham, MA), whereas MCF7 and MCF7HER2 cells were cultured in Roswell Park Memorial Institute medium (RPMI-1640,
Thermo Fischer Scientific, Waltham, MA). The cell culture medium was supplemented
with 10% fetal bovine serum (FBS, Gemini Bio-Products, West Sacramento, CA), 1% Lglutamine (2 mM, Thermo Fischer Scientific, Waltham, MA) and 1% non-essential
amino acids (100 µM, Invitrogen, Carlsbad, CA). All the cell lines were authenticated
using short tandem repeat allelic profiling (DCC Medical). All the cell lines were
maintained by incubating them at 370C with 95% O2 and 5% CO2.
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Drugs, Chemicals, and Reagents
Gamma-Secretase Inhibitors
GSIs act by preventing the final proteolytic cleavage of the Notch receptor which
is mediated by the gamma-secretase complex and thus prevents Notch activation.
MRK-003 GSI was provided by Merck Oncology & Co. (Whitehouse Station, NJ). MRK003 GSI is a small molecule inhibitor and it acts by binding to the binding pocket of
presenilin, the catalytic subunit of gamma-secretase complex. For in vitro studies, 5 mM
MRK-003 GSI stock solution was prepared by dissolving it in dimethyl sulfoxide
(DMSO). The working concentration was 5 µM and the prepared drug was stored at 800C for future use.
Lapatinib
Lapatinib is a dual HER2-EGFR tyrosine kinase inhibitor. It was purchased from
Selleck Chemicals (Houston, TX, Cat. S1028). For in vitro studies, 4 mM stock
concentration of lapatinib was prepared by dissolving it in DMSO. The working
concentration was 2 µM and the prepared drug was stored at -800C for future use.
Matrigel
Basement membranes are thin extracellular matrices underlying cells in vivo.
Corning® Matrigel® Basement Membrane Matrix (Tewksbury, MA, Cat. 354234) is a
solubilized basement membrane preparation extracted from the Engelbreth-HolmSwarm (EHS) mouse sarcoma, a tumor rich in extracellular matrix proteins. Its major
component is laminin, followed by collagen IV, heparan sulfate proteoglycans,
entactin/nidogen. Corning Matrigel Basement Membrane Matrix also contains TGF-β,
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epidermal growth factor, insulin-like growth factor, fibroblast growth factor, tissue
plasminogen activator, and other growth factors which occur naturally in the EHS tumor.
Matrigel has been used for the CSC model and its use has been shown to enhance
tumor growth rates in vivo.
RNA Interference and Transfection Reagents
Jagged1 stealth siRNA having two different sequences was purchased from
Thermo Fisher Scientific (Waltham, MA, Cat. HSS176254 and HSS176255). HER2
siRNA was purchased from Origene (Rockville, MD, Cat. SR301443). Notch1 siRNA
was purchased from Dharmacon (Lafayette, CO, Cat. HSS107248). Notch3 and Notch4
siRNAs were purchased from Santa Cruz Biotechnology, (Santa Cruz, CA, Cat. sc37135 and sc-40137). Non-targeting scrambled control siRNA was purchased from
Qiagen (Germantown, MD, Cat. 1027281). The transfection reagents Lipofectamine
3000 (Cat. L3000015) and Lipofectamine RNAimax (Cat. 13778150) were purchased
from Thermo Fisher Scientific (Waltham, MA). Lipofectamine 3000 was used for
Jagged1 knockdown and Lipofectamine RNAimax was used to knockdown HER2,
Notch1, Notch3, and Notch4. The siRNAs were reconstituted with RNAse free water to
yield a stock concentration of 10 µM. The final working concentration of the siRNA was
10 nM. For Jagged1 siRNA transfection, 17 µl siRNA and 17 µl of lipofectamine 300
were used in a 60mm plate. For HER2, Notch1, Notch3 and Notch4 siRNAs
transfection, 20 µl of siRNA and 20 µl RNAimax was used in a 60mm plate. The
transfection was performed according to the manufacturer’s protocol. The sequences of
each of the siRNA used is listed below -
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siRNA

Sequence (5’-3’)

Jagged1 A

GATAACTGTGCGAACATCACATTTA

Jagged1 B

CGCGACGAGTGTGACACATACTTCA

HER2

rGrCrCrArArCrArArArGrArArArUrCrUrUrArGrArCrGrAAG

Notch1

ACGAAGAACAGAAGCACAAAGGCGG

Notch3

GUCAGAAUUGUGAAGUGAAtt
CUCGUCAGUUCUUAGAUCUtt
CCUCUCAUUUCCUUACACUtt
GAACCUGGAUGACUGUAUUtt
GCAGGCAUAUGGGAUGUAAtt
CCACUGCUAUCGCUAUUUAtt
Sequence held by Qiagen

Notch4

Scrambled
Control

Table 3: siRNA Sequences.
Antibodies
Phospho-HER2 (Tyr 1221/1222) (6B12) antibody was purchased from Cell
Signaling Technology (Danvers, MA, Cat.2243). Total HER2 antibody (e2-4001 + 3B5)
was purchased from Thermo Fisher Scientific (Waltham, MA, Cat. MA5-14057).
Jagged1 (C20) antibody was purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, Cat. sc-6011). Notch3 antibody was purchased from Abcam (Cambridge, MA, Cat.
ab23426). Notch1 antibody was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, Cat. sc-376403). Notch4 antibody was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, Cat. sc-5594). Beta Actin (AC-15) antibody was
purchased from Sigma-Aldrich (St. Louis, MO, Cat. A5441). Beta Actin was used as
endogenous control for all the western blots. Secondary antibodies - donkey anti-mouse
IgG-HRP (1:5000, Cat. sc-2314), donkey anti-rabbit IgG-HRP (1:2000, Cat. sc-2313),
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and donkey anti-goat IgG-HRP (1:2000, Cat. sc-2020) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA).
Western Blot Analysis
HCC1954, MDA-MB-453, MCF7 and MCF7-HER2 cells were transfected with
siRNA and/or treated with 2 µM lapatinib for 4 days. The cells were maintained in the
incubator at 370C with 95% O2 and 5% CO2. Followed by the transfection and/or
treatment, the medium was aspirated and the cells were washed twice using ice cold
phosphate-buffered saline (PBS). Depending upon the cell confluency and the size of
the plate, 150 µl-300 µl of Triton X-100 lysis buffer (50 mM 4-(2-hydroxyethyl)-1piperazineethanesulfonic acid (HEPES), 1% Triton X-100,150 mM sodium chloride
(NaCl), 5 mM ethylenediaminetetraacetic acid (EDTA), 1 mM phenylmethylsulfonyl
fluoride (PMSF), 1 mM sodium orthovanadate, 10 mM sodium fluoride (NaF), 1
protease inhibitor cocktail tablet) was used to lyse the cells. The cells were then
scraped using cell scraper, and the lysate was collected into Eppendorf tubes. The
collected cell lysate was allowed to sit on ice for 10 minutes. Followed by that, the cells
were sonicated thrice for 10 seconds each using the Sonic Dismembrator (Model 100,
Thermo Fischer Scientific, Waltham, MA). After the sonication, the Eppendorf tubes
were centrifuged at maximum speed for 30 minutes at 40C. The supernatant was
collected after centrifugation, and the protein concentration was determined using
Pierce bicinchoninic acid (BCA) Protein Assay kit (Thermo Fisher Scientific, Waltham,
MA, Cat. 23225). To 10 µl of test or standard protein sample (triplicates), 200 µl of the
reagent mix (50 parts reagent A and 1 part reagent B) was added in the well of a 96 well
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plate. Standards were prepared by dissolving bovine serum albumin (BSA) in PBS
(Standards – 0 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 6 mg/ml, 8 mg/ml and 10
mg/ml). The plate was incubated for 30 mins at 370C and was read using a 96 well plate
reader at 562 nm. Based on the standard curve generated, the protein concentration of
the test samples was determined. Based on the protein concentration, protein samples
were prepared (20 µg – 50 µg) using 2X or 4X Laemmli buffer (BioRad, Hercules, CA,
Cat. 1610737 or 1610747) and beta-mercaptoethanol (Thermo Fischer Scientific,
Waltham, MA, Cat. BP-176-100). The prepared samples were boiled at 950C for 5
minutes. The denatured protein samples were then run on 7% tris-acetate gels (Thermo
Fisher Scientific, Waltham, MA, Cat. EA0358BOX) along with HiMark Prestained protein
standard (Thermo Fisher Scientific, Waltham, MA, Cat. LC5699) at 150V for 60 minutes.
20X NuPAGE Tris-Acetate SDS Running Buffer (Thermo Fisher Scientific, Waltham,
MA, Cat. LA0041) was diluted using deionized water for the usage. The separated
proteins were then transferred onto Polyvinylidene difluoride (PVDF) membrane. The
transfer was performed at 40V for 120 minutes using 1X transfer buffer (NuPAGE® 20x
Transfer buffer was diluted to 1x in deionized water, 20% methanol). The 20x transfer
buffer was purchased from Invitrogen (Cat. NP006 Grand Island, NY). The transfer
assembly included 3 sponges presoaked in transfer buffer for 30 mins, 1 filter paper, the
gel, PVDF membrane presoaked in methanol and rinsed in water and transfer buffer, 1
filter paper and 3-4 presoaked sponges. After the transfer, the membrane was rewetted
in methanol and water and was blocked using 5% non-fat dry milk, 20% Roche buffer or
5% BSA (used for phosphorylated proteins) for 1 hour at room temperature. TBST (5
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mM Tris-HCl, 5 mM Tris-base, 150 mM NaCl, 0.05% Tween-20, and 0.2% NP-40 at pH
8.0) was used for the dilution of non-fat dry milk or BSA, whereas tris-buffered saline
(TBS) was used for the dilution of Roche buffer. After the blocking, the membrane was
incubated overnight with the primary antibody at 40C with constant shaking. The primary
antibody was diluted at the recommended concentration using the diluent that was used
for blocking. The following day, the membrane was washed thrice using TBST. Each
wash was for 10 minutes and the blots were shaken vigorously at room temperature.
After the three washes, the secondary antibody was added and the membrane was
incubated at room temperature for 1 hour, with constant rocking. The dilution buffer for
the secondary antibody was the same as the one used for primary antibody. Followed
by this, the membrane was again washed for three times using TBST as mentioned
before. After the final wash, the proteins were detected by covering the membrane
using enhanced chemiluminescence (ECL) Western blotting substrate (Pierce,
Rockford, IL) or SuperSignal® West Dura (Thermo Fischer Scientific, Waltham, MA)
added in 1:1 volume. The membrane was incubated for 1 minute at room temperature.
The protein bands were visualized after allowing the membrane to expose onto the Xray film in the dark room for the necessary timeframe.
To reprobe the membrane, it was washed in TBST at room temperature for 10
minutes. The membrane was then stripped using Restore Plus Western Blot Stripping
buffer (Thermo Fischer Scientific, Waltham, MA). The membrane was covered with the
stripping buffer and was incubated for 20 minutes at 370C. Followed by this, the
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membrane was washed three times using TBST as mentioned before. The membrane
was then blocked and probed with the primary antibody of interest.
Protein
Jagged1
Notch1
Notch3
Notch4
Total HER2
Phospho-HER2 (Tyr
1221/1222)
Beta Actin

Blocking Reagent
20% Roche
20% Roche
20% Roche
20% Roche
5% nonfat dry milk
5% BSA

Antibody Dilution
1:1000
1:500
1:1000
1:1000
1:1000
1:500

5% nonfat dry milk

1:5000

Table 4: Western Blotting Specifications.
Flow Cytometry
HCC1954 (250k cells/well – 6 well plate) and MDA-MB-453 cells (350k cells/well6 well plate for treatment and 700k cells/well-60 mm plate for transfection) were either
transfected with HER2 siRNA for 48 hours or treated for four days with 2 µM lapatinib
and the impact of genetic or pharmacologic inhibition of HER2 on the surface
expression of Jagged1 was assessed by using flow cytometry. Scrambled siRNA and
DMSO were used as negative controls. For 4 days of lapatinib treatment, HCC1954
cells were trypsinized and replated after 2 days at a similar density. This was done to
prevent the cells from becoming overconfluent. MCF7 (40k cells/well-6 well plate) and
MCF7 HER2 (40k cells/well-6 well plate) were similarly treated for 4 days with 2 µM
lapatinib using DMSO as a control.
The cultured cells were harvested using Cellstripper (Corning Cellgro, Manassas,
VA, Cat. 25-056-CI). The harvested cells were neutralized using DMEM and the cell
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suspension was centrifuged at 1300 rpm for 3 minutes. Followed by this, the cell pellet
was resuspended in 2 ml flow cytometry staining buffer (R&D Systems, Minneapolis,
MN, Cat. FC001) and the cell suspension was transferred into FACS tube. The cells
were then washed twice with 2 ml flow cytometry staining buffer by centrifuging the cell
suspension at 1300 rpm for 3 minutes. After the second wash, the excess staining
buffer was aspirated, while leaving about 250 µl of buffer and the cell pellet. The cells
were then stained using biotinylated human Jagged1 primary antibody (R&D Systems,
Minneapolis, MN, Cat. BAF1277). About 6 µl of the primary antibody was added to the
tube containing 100k-1 million cells. The cell suspension containing the antibody was
then incubated for 45 minutes at room temperature. Followed by the incubation, the
cells were washed twice using the flow cytometry staining buffer by centrifuging them at
1300 rpm for 3 minutes. After the second wash, excess staining buffer was aspirated,
leaving behind around 250 µl. To this cell suspension, APC conjugated secondary
antibody (BioLegend, San Diego, CA, Cat. 405207) was added. All the subsequent
steps were performed in the dark. The secondary antibody was diluted 20-fold using
flow cytometry staining buffer and then about 8 µl of the antibody was added to the tube
containing 100k – 1 million cells. The tubes were then incubated at room temperature
for 45 minutes. After the incubation, the tubes were washed twice with flow cytometry
staining buffer as described before. The cell pellet was finally resuspended in 250 µl of
flow cytometry staining buffer for analysis by using BD FACS Canto II (BD BioSciences,
San Jose, CA). Data was attained using BD FACSDiva software. Data analysis was
performed using FlowJo software (FlowJo LLC, Ashland, OR).
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For CD44 High/CD24 low assay, HCC1954 cells were harvested and stained per
the protocol mentioned above. The cells were stained with APC conjugated CD44
(BioLegend, San Diego, CA, Cat. 103012)/ FITC conjugated CD44 (BioLegend, San
Diego, CA, Cat. 103021) and PE conjugated CD24 (BioLegend, San Diego, CA, Cat.
311106), and were analyzed as mentioned above.
For assessing the surface expression of Notch receptors, Notch1-PE
(BioLegend, San Diego, CA, Cat. 352106), Notch3-PE (BioLegend, San Diego, CA, Cat.
345406), and Notch4-PE (BioLegend, San Diego, CA, Cat. 128407) antibodies were
used.
Cell Sorting
HCC1954 cells were treated with 2 µM lapatinib for 4 days, and were stained
with biotinylated Jagged1 (40 µl) and streptavidin-APC antibodies (5 ul undiluted) as
described before. To sort sufficient cells, 3 T150 flasks (4 million cells/flask) were used
for DMSO treatment and 7-8 T150 flasks (4.5 million cells/flask) were used for lapatinib
treatment. Followed by the staining, the cells were sorted based on Jagged1 surface
expression (DMSO Jagged1-low and lapatinib Jagged1-high) by using BD FACSAria
cell sorter (BD BioSciences, San Jose, CA). The cells were sorted into 24 well plate
containing mammosphere medium (35k cells/well) supplemented with DMSO/ 5 µM GSI
for performing mammosphere assay. The cells were sorted into the FACS tube for
performing aldefluor assay, for CD44 high/CD24 low assessment, and for detecting the
expression of Notch target genes. Followed by the sort in the tubes, the cell suspension
was centrifuged at 1300 rpm for 3 minutes, and the cells were then used for performing
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the necessary assay. The detailed protocols for mammosphere assay, aldefluor assay,
CD44 high/CD24 low assessment and detection of Notch target genes using real-time
polymerase chain reaction (PCR) have been described.
A control experiment was performed whereby HCC1954 cells (3 T150 flasks)
were stained for the detection of Jagged1 surface expression as mentioned above, and
Jagged1 high and Jagged1 low cells were sorted (25k cells/well) into 24 well plate
containing mammosphere medium supplemented with DMSO/ 5 µM GSI.
Mammosphere formation was assessed as described in the protocol.
Aldefluor Assay
ALDH1 is one of the 19 ALDH isoforms expressed in humans and is believed to
be responsible for ALDH activity of CSCs. ALDH is a detoxifying enzyme and is
responsible for the oxidation of intracellular aldehydes. Aldefluor kit (STEMCELL
Technologies, Vancouver, Canada, Cat. 01700) was used to perform the aldefluor
assay to detect the CSC population based on the enzymatic activity of ALDH1 isoform.
Two tubes containing 200k sorted/ unsorted HCC1954 cells suspended into 1ml
of aldefluor assay buffer were prepared – a test tube that received 5 µl ALDH1
substrate, and the control tube that received 10 ul N, N-diethylaminobenzaldehyde
(DEAB), the inhibitor of aldehyde dehydrogenase and 5 µl substrate. Followed by this,
the tubes were incubated at 37oC for 45 minutes in the dark. After the incubation, the
tubes were put on the ice and were centrifuged for 5 mins at 250g. The supernatant was
then removed and the cell pellet was resuspended, into 0.5 ml Aldefluor assay buffer.
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The tubes were then put on the ice and were analyzed using flow cytometry as
mentioned before.
Mammosphere Assay
Preparation of Methyl Cellulose Based Mammosphere Medium.
196 ml of DMEM-F12 medium (Gibco, Gaithersburg, MD, Cat. 11039021) was
warmed at 60oC and added to a bottle containing 2 grams of methyl cellulose. The
contents were then allowed to stir at 60oC for about 2.5 hrs. until methyl cellulose is
uniformly mixed. Followed by this, the DMEM-F12 methyl cellulose medium was stirred
overnight at 4oC. The following day, 4 ml B-27 supplement and 4 µl recombinant hEGF
(Sigma-Aldrich, Milwaukee, WI, Cat. E-9644) was added to the medium. The medium
was then stirred at 4oC for about 30 mins and then transferred into centrifuge tubes. The
tubes were then spun at 9500 rpm in Beckman rotor at 40C for 30 mins. The
supernatant (mammosphere medium) was poured into 50 ml conical tubes after
centrifugation. The tube containing mammosphere medium was incubated in a bead
bath at 370C for 2-3 hours prior to use. Excess mammosphere medium was stored at
-200C.
Mammosphere Assay Protocol.
To perform mammosphere assay, the cells were harvested using trypsin or
sorted. The single cell suspension was prepared and 100,000 cells/well (6 well ultra low
attachment plate) or 35,000/25,000 cells/well (24 well ultra low attachment plate) were
added into the mammosphere medium containing vehicle control DMSO or 5 µM MRK003 GSI.
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To study the effect of Jagged1, Notch1, Notch3 or Notch4 knockdown, 600k
HCC1954 cells were plated into 60mm plate. 3 plates each were used for transfection of
scrambled control siRNA or Jagged1, Notch1, Notch3, or Notch4 siRNA. The
transfection was performed as mentioned before. After the transfection, the cells were
harvested and were replated for DMSO or lapatinib treatment for 4 days. After the
treatment, 100k cells in a single cell suspension was used for the mammosphere assay
and the remaining cells were used to perform western blot. The western blot protocol is
described later.
After the addition or sorting of the cells, the mammosphere plate was rocked
back and forth several times to ensure that the cell suspension is evenly distributed
across the well. The mammosphere plates were then left in the incubator at 37 0C and
5% CO2 for seven days. After seven days, the mammospheres were harvested and
counted.
To harvest the mammospheres, about 2 ml PBS was added to the well
containing mammospheres. The mixture of PBS and mammospheres was pipetted
gently a few times and was transferred into 15 ml conical tube. This process was
repeated 3-4 times until all the mammospheres were harvested. The plate was
observed under the microscope to ensure that all the mammospheres were harvested.
The 15 ml conical tube containing the mammosphere suspension was spun down at
1500 rpm for 5 minutes. Followed by this, the supernatant was aspirated and 2 ml PBS
was added to the mammosphere pellet. The mix was then transferred to a 2ml tube and
was spun at 5000 rpm for 5 mins. One more wash with 2 ml PBS was performed and
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then the mammosphere pellet was again resuspended in 2ml PBS (2 ml PBS was used
as resuspension volume if 100k cells were plated. For 35,000 sorted cells, 500 µl PBS
was used for resuspension). After resuspension, 50 µl was transferred into a well of a
96 well plate. 350 µl PBS was then added to the well of 96 well plate. Followed by this,
the well containing mammospheres was observed under a microscope and five pictures
were taken at 4X magnification. The pictures contained measurement scale. Taking five
pictures ensured that the pictures captured all the mammospheres that were present in
the well. The pictures were then transferred into PowerPoint and the mammospheres
were manually counted, based on the scale present in the picture. The size cut-off was
50 µm i.e. all the spheres ≥ 50 µm were counted as mammospheres. Based on
resuspension volume, the dilution factor was used to count the total mammospheres.
%MFE was defined as
100*(Number of mammospheres/ number of cells plated).
In Vivo Study
HCC1954 cells were treated with either vehicle control i.e. DMSO or 2 µM
lapatinib for 4 days and then were sorted on the basis of Jagged1 surface expression.
The sorted cells were diluted in PBS and mixed with Matrigel (1:1 ratio) before injecting
them into mammary fat pads of ovariectomized FoxN1 nu/nu athymic nude mice (Harlan
Sprague-Dawley, Madison, WI). 100 µl of cell suspension was injected at each site.
During the study, each mouse and its tumor were tracked using an ear tag. To perform
limiting dilution assay to detect the frequency of CSC formation, the mice were
randomized into following groups–
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100/ 1k/ 10k Vehicle Control i.e. DMSO Jagged Low cells/site (n=8 or 10 per group)
100/ 1k/ 10k Lapatinib Jagged High cells/site (n=8 or 10 per group)
One week after the injection, the tumor formation was assessed weekly. Tumors
were measured by using Vernier calipers and the tumor area (l x w) was calculated and
graphed. At the end of seven weeks, the number of mice that developed tumor ≥ 40
mm2 were counted and the tumor initiating potential was calculated by using the ELDA
software (Hu and Smyth 2009). All the protocols for the animal study were approved by
Loyola University’s Institutional Animal Care and Use Committee (IACUC).
Immunohistochemical Staining of Human HER2+ Breast Tumors
The HER2+ breast tumor tissue was allowed to adhere by placing the tissue
microarray sections in oven at 58oC to 60oC. The sections were deparaffinized using
xylene, rehydrated through graded ethanol and washed with PBS prior to 1X Reveal
treatment in a Decloaking Chamber (Biocare Medical) for antigen retrieval. The
procedure was performed according to the manufacturer's protocol. Followed by the
PBS rinse for 15 minutes, the sections were soaked in 3%H2O2 in PBS for 20 minutes to
quench endogenous peroxidase activity. To block non-specific binding, the sections
were incubated for one hour in 3% normal rabbit serum (Vector Laboratories) in PBS at
room temperature. After blocking, the sections were probed with primary Jagged1
antibody prepared in PBS containing 1.5% normal rabbit serum for one hour and were
incubated in a hydrated chamber at room temperature. Tissue Microarray (TMA)
sections incubated with 1μg/ml normal goat IgG (Santa Cruz Biotechnologies, CA) were
used as negative controls. Pilot experiments were performed to determine the best
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antibody concentration and to minimize the background. Following extensive washing,
antigen-antibody complexes were detected using the Vectastain Elite ABC kit (Vector
Laboratories, CA) as per the manufacturer’s protocol. Staining was performed with
ImmPactTM DAB peroxidase substrate kit (Vector Laboratories, CA). Sections were
then counterstained with Gill’s hematoxylin and dehydrated in ascending grades of
ethanol before clearing in xylene and mounting under a coverslip using Cytoseal XYL.
The levels of Jagged1 protein expression in each specimen were scored per the extent
(percent of stained cells) and intensity of staining. The score for the extent of the IHC
stained area was scaled as 0 for no IHC signal at all and 1 for 10–80 tumor cells
stained. Stained slides were sent to Nottingham, England where they were scanned.
High-resolution images were uploaded to the Nottingham web-accessible scoring site,
and were scored by 2 independent investigators (He Zhu and Lucio Miele). Intensity
scores (0-1), percent staining scores and H-Scores were uploaded as Excel
spreadsheets and survival analysis was performed using SPSS.
Real-Time PCR
HCC1954 cells were treated for four days with 2 µM lapatinib. Followed by this,
the cells were sorted on the basis of Jagged1 surface expression as mentioned before.
For unsorted cells, the total RNA was extracted according to the manufacturer’s
protocol using RiboPure RNA Purification kit (Ambion, Austin, TX, Cat. AM1924). For
the cells that were sorted on the basis of Jagged1 surface expression, RNeasy Plus
Micro Kit (Qiagen, Germantown, MD, Cat. 74034) was used for RNA extraction, as this
kit is more suitable for small number of cells. After the extraction, the RNA yield was
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determined by using the NanoDrop Spectrophotometer (Thermo Fischer Scientific,
Waltham, MA). cDNA was synthesized through reverse transcription by using 1 µg RNA
in 100 µl volume containing 1X RT buffer, 5.5 mM MgCl2, 500 µM dNTPs, 2.5 µM
random hexamers, 0.4 U/µl RNase inhibitors, and 1.25 U/µl RT enzyme (MultiScribe™
Reverse Transcriptase Kit, Applied Biosystems, Foster City, CA, Cat. N8080234). For
reverse transcription, the parameters were as follows: 10 minutes at 25 0C, 30 minutes
at 480C, 5 minutes at 950C, 60 minutes at 250C, and at 40C until use. After the cDNA
was synthesized, real-time PCR was performed using iTaq™ SYBR® Green Supermix
with ROX (BioRad, Hercules, CA).to detect the transcript levels of Notch receptors and
Notch target genes. In a 96 well plate, 2.5 µl of prepared cDNA was added to 22.5 µl of
mastermix containing 2X SYBR Green Universal Master Mix, and 50 µM forward and
reverse primers of the intended target. The assay was performed in triplicates. The
plate was then sealed to prevent evaporation and quantitative Real Time PCR was
performed using following parameters: the initial denature temperature was for 10
minutes at 950C; PCR cycling for 40 cycles was carried out for 10 seconds at 950C, and
for 45 seconds at 600C. A melt curve was added after completion of the 40 cycles set by
the StepOnePlus thermocycler manufacturer (Applied Biosystems, Foster City, CA). At
the end of the run, relative expression of various genes in different samples was
calculated based on the Ct value. Ct value indicates the number of cycles that were
required to detect a real signal from the sample. Lower Ct value is suggestive of more
abundant gene expression in the sample, as fewer cycles were required to generate a
real signal. Similarly, higher Ct value is indicative of less abundant gene expression in
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the sample. Hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene was used
as endogenous control for normalizing the Ct values. Relative fold change in the gene
expression between different samples was calculated on the basis of 2 (-Delta Delta Ct)
methodDelta Ct sample = (Ct value of gene of interest (sample) - Ct value of HPRT(sample))
Delta Ct control = (Ct value of gene of interest (control) - Ct value of HPRT(control))
Delta Delta Ct = (Delta Ct sample - Delta Ct control)
Fold change in gene expression = 2 (-Delta Delta Ct)
The primer sequences that were used for detecting the gene expression of various
genes are listed below:
Target
Forward Primer (5’-3’)
Reverse Primer (5’-3’)
Notch1
ATCAACGCCGTAGATGACC
TTGTTAGCCCCGTTCTTCAG
Notch2
TGGTTCAGAGAAAACATACA
TCCACTTCATACTCACAGTTGA
Notch3
TCCTGGCTACAATGGTGATAAC
ATTAATCTCGCAGAGCACCC
Notch4
TGCAGGCATATGGGATGTAA
CATCCCCACAGTGGAGTTCT
Jagged1
GACTCATCAGCCGTGTCTCA
TGGGGAACACTCACACTCAA
HES1
CGGACATTCTGGAAATGACA
CATTGATCTGGGTCATGCAG
HEY1
TCATTTGGAGTGTTGGTGGA
CTCGCACACCATGATCACTT
CYCLIND1
GTCCATGCGGAAGATCGTC
GCGGTCCAGGTAGTTCATG
HES4
GAGCGCGTATTAACGAGAGCCT CTCACGGTCATCTCCAGGATGT
C-MYC
CCTACCCTCTCAACGACAGC
CTCTGACCTTTTGCCAGGAG
HEY2
AAAAGGCGTCGGGATCG
AGCTTTTTCTAACTTTGCAGATCC
HPRT
ATGAACCAGGTTATGACCTTGAT CCTGTTGACTGGTCATTACAATA
Table 5: Primer Sequences.
Statistical Analysis
Most of the experiments were performed three times and the results were
reported as Mean± Standard Deviation (S.D.). For data involving two comparisons,
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Microsoft Excel was used to perform a two-tailed Student’s t-test. Multiple comparisons
were assessed using analysis of variance (ANOVA) (Tukey’s test for multiple
comparisons) and GraphPad Prism 6 was used for the analysis. All the graphs were
generated using GraphPad Prism 6.
For real-time PCR, the graphs were plotted based on the Relative Quantitation
(RQ) value, and the error bars represented S.D.. To determine the statistical
significance, delta Ct values were used for performing the t-test.
ELDA software was used to calculate CSC frequency for the limiting dilution in
vivo study.
Kaplan-Meier curve for the overall survival of women suffering from HER2+
breast cancer was created through GraphPad Prism 6 and the data was analyzed with a
log-rank Mantel-Cox test.

CHAPTER IV
HYPOTHESIS AND SPECIFIC AIMS
Despite improved prognosis for women with the HER2-positive subtype of breast
cancer due to the availability of targeted therapy, drug resistance, and tumor recurrence
remains a major concern. About 20-50% of the women that are suffering from HER2+
metastatic breast cancer exhibit intrinsic resistance whereas 10-15% of the women
treated with trastuzumab plus adjuvant chemotherapy develop acquired resistance
within the first year of drug treatment (Hudis 2007, Valabrega, Montemurro et al. 2007)
Previous findings suggest that HER2 restricts Notch activation and inhibition of
HER2 using inhibitors such as trastuzumab or lapatinib results in Notch1 activation
(Osipo, Patel et al. 2008). Studies reveal that high levels of Notch1 receptor and its
ligand Jagged1 correlate with worst prognosis for women with breast cancer (Reedijk,
Odorcic et al. 2005). We have previously shown that Notch1 and Jagged1 contribute to
trastuzumab resistance (Osipo, Patel et al. 2008, Pandya, Wyatt et al. 2016).
Furthermore, the in vivo work revealed that dual blockade of HER2 and Notch activation
prevents HER2+ tumor recurrence suggesting the critical role of Notch activation in a
subset of cells for HER2+ tumor recurrence (Pandya, Meeke et al. 2011). Moreover,
there have been reports about the roles of Notch1, Notch3 or Notch4 receptors for the
survival of breast CSCs (Yao, Rizzo et al. 2011). However, the exact mechanism by
which Notch activation upon HER2 blockade leads to the formation of a subset of cells
74

75

responsible for drug resistance and tumor recurrence [also known as CSCs] is yet
unknown.
Since Notch signaling works in a contact dependent fashion with the ligand being
expressed on the signal sending cell and the receptor being expressed on the signal
receiving cell, we hypothesized that HER2 restricts Notch activation through its ligand
Jagged1 as high levels of Jagged1 are sufficient to predict poor outcome in women with
breast cancer (Reedijk, Pinnaduwage et al. 2008). Previous work suggests that
increased Notch activation in response to HER2 blockade is dependent on Jagged1
expression. Furthermore, dual blockade of HER2 and Jagged1 inhibited cell
proliferation in vitro and reversed drug resistance in vivo (Pandya, Wyatt et al. 2016).
Taken together, these results suggest that Jagged1-mediated Notch activation upon
HER2 inhibition leads to cell proliferation, drug resistance and possibly tumor
recurrence. In addition, previous work has shown that Jagged1 is involved in the
survival and self-renewal of breast CSCs from ER+ or the triple negative basal- like
subtype of breast cancer (Sansone, Storci et al. 2007, Xu, Usary et al. 2012). Based on
the preliminary data, I hypothesize thatHER2 blockade of HER2+ breast cancer cells enriches a Jagged1-positive
subset of CSCs that are resistant to anti-HER2 treatment and responsible for tumor
initiation.
The hypothesis will be tested by following aimsSpecific Aim 1-Determine whether surface expression of Jagged1 is critical for the
formation of CSCs.
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Specific Aim 2-Assess the ability of Jagged1 high subpopulation to form a tumor in vivo
and to measure its CSC potential.
Data from our studies will delineate the mechanism by which Notch activation
upon HER2 inhibition leads to the formation of CSCs in HER2+ breast cancer. It will
elucidate for the first time that HER2 inhibits the formation of CSCs by limiting the
expression of Jagged1 on the cell surface and thus Jagged1 mediated Notch activation.
Moreover, our studies would identify Jagged-1 as a potential novel therapeutic target for
preventing the enrichment of CSCs that mediate drug resistance and tumor recurrence
in HER2+ breast cancer. Furthermore, our studies would provide a preclinical proof of
concept for future clinical trials using HER2 inhibitor in combination with Notch pathway
inhibitor (Jagged1 targeted therapy) to inhibit the enrichment of CSCs and thus prevent
drug resistance and tumor recurrence in HER2+ breast cancer.
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Figure 5: Hypothesis of the Investigation.
HER2 restricts Jagged1 surface expression. Inhibition of HER2 results in an increase in
Jagged1 on cell surface leading to higher Notch activation, CSC formation and poor
overall patient survival. Dual inhibition of Jagged1 and HER2 will effectively destroy bulk
cells as well as CSCs, and thus improve overall patient survival.

CHAPTER V
RESULTS
Specific Aim 1–Determine Whether Surface Expression of Jagged1 Is Critical for
the Formation of CSCs
Specific Aim 1 will be tested by following subaims:
Aim 1A-Determine whether Jagged1-high subpopulation upon lapatinib treatment results
in an increase in the formation of CSCs as compared to Jagged1-low subpopulation in
the absence of lapatinib treatment. CSCs would be assessed by %MFE, aldehyde
dehydrogenase activity and the levels of CD44 High/CD24 Low.
Aim 1B-Assess whether Jagged1 is necessary for lapatinib mediated enrichment of
mammospheres in the HER2+ subtype of breast cancer.
Aim 1C-Measure the degree of Notch activation in Jagged1-high subpopulation upon
lapatinib treatment and in the Jagged1-low subpopulation in the absence of lapatinib
treatment.
Aim 1D-Identify the Notch receptor that interacts with Jagged1 to cause lapatinib
mediated enrichment of mammospheres in the HER2+ subtype of breast cancer.
Since Notch activation was required for tumor recurrence, we wanted to test if
Notch activation is necessary for the formation of CSCs derived from HER2+ breast
cancer cells.
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To address this, HCC1954, MCF7, and MCF7-HER2 cells were treated for 4
days with 2 µM lapatinib. HCC1954 is a HER2+ breast cancer cell line. MCF7 cells do
not overexpress HER2, whereas MCF7-HER2 cells constitutively overexpress HER2.
DMSO was used as a vehicle control. In order to ensure that lapatinib was able to
effectively inhibit the tyrosine kinase activity of HER2, protein was harvested and
Western blot was performed to detect phosphor-HER2 (Tyr 1221/1222), total HER2 and
Beta actin in MCF7 (Figure 6A), MCF7-HER2 (Figure 6D), and HCC1954 cells (Figure
6G). Beta actin was used as a loading control.
For the mammosphere assay, after the drug treatment, the cells were harvested
and the total number of cells present in the single cell suspension were counted. 50,000
MCF7 cells/MCF7- HER2 cells and 100,000 HCC1954 cells (DMSO or lapatinib treated)
were plated in an ultra-low attachment plate containing mammosphere medium
supplemented with 5 µM GSI or vehicle control DMSO. The mammosphere formation
was assessed after 7 days and representative pictures were taken [MCF7 (Figure 6B),
MCF7-HER2 (Figure 6E), and HCC1954 (Figure 6H)]. The mammospheres were then
collected and %MFE was determined. The results showed that HER2 inhibition using
lapatinib results in an increase in survival of CSCs as measured by %MFE only in
HER2+ breast cancer cells [MCF7-HER2 (Figure 6F) or HCC1954 (Figure 6I)] and not
in non-overexpressing cells (MCF7) (Figure 6C). Mammosphere formation of all cells
was prevented using a GSI, confirming reports that Notch activation is mediated by
gamma-secretase cleavage. This suggested that HER2 inhibition resulted in
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enhancement of CSC formation, as assessed by mammopshere forming efficiency, and
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Figure 6: Lapatinib Mediated Inhibition of HER2 Tyrosine Kinase Activity Results
in Notch Activation Dependent Increase in Mammosphere Formation.
MCF7 cells (HER2-, i.e. lacks HER2 overexpression), MCF7-HER2 cells (HER2+), and
HCC1954 cells (HER2+) were treated with vehicle control i.e. DMSO/ 2 µM lapatinib for
4 days and mammosphere forming assay was performed.
(A) MCF7, (D) MCF7-HER2, and (G) HCC1954. Representative western blot showing
the effect of lapatinib treatment on the levels of phosphorylated HER2 (Tyr 1221/1222)
and total HER2. Beta actin was used as a loading control.
(B) MCF7, (E) MCF7-HER2, and (H) HCC1954.Effect of lapatinib treatment on
mammosphere formation was assessed after 7 days. The pictures are representative of
three independent experiments.
(C) MCF7, (F) MCF7-HER2, and (I) HCC1954.The %MFE was determined and the data
represents the average of three independent experiments. Error bars represent S.D.
and the statistical significance was calculated using ANOVA for multiple comparisons.
GraphPad Prism was used for the analysis. * p<0.05, **p<0.01, *** p<0.001,
****p<0.0001.

Since the data supported the hypothesis that HER2 restricted the Notch
activation, and previously we showed that Jagged1 was required for the Notch
activation (Pandya, Wyatt et al. 2016), the question that we asked was – does HER2
affect the surface expression of Jagged1? Higher Jagged1 mRNA and protein levels do
predict poor prognosis for women with breast cancer (Dickson, Mulligan et al. 2007). To
address this question, HER2+ cells: HCC1954, MDA-MB-453, MCF7-HER2 and HER2low MCF7 cells were treated with 2 µM lapatinib for 4 days, and the surface expression
of Jagged1 was measured by using flow cytometry. Figure 7 demonstrates the
effectiveness of lapatinib treatment on phosphorylation of HER2 in MDA-MB-453 cells.
Figure 6A, 6D and 6G shows the effect of lapatinib treatment on HER2 phosphorylation
in MCF7, MCF7-HER2 and HCC1954 cells respectively. HER2 inhibition using lapatinib
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resulted in an increase in the surface expression of Jagged1 in HCC1954 (Figure 8A),
MDA-MB-453 (Figure 8B), and MCF7 HER2 cells (Figure 8D). No effect of lapatinib was
observed in the MCF7 cells that do not overexpress HER2 but have higher levels of
EGFR (Figure 8C). This would suggest that the increase in Jagged1 surface levels
observed with lapatinib treatment is specifically due to inhibition of HER2 tyrosine
kinase activity and not by lapatinib mediated inhibition of EGFR tyrosine kinase activity.
To genetically inhibit HER2, HCC1954 and MDA-MB-453 cells were transfected with a
HER2 siRNA or scrambled control siRNA for 48 hours. Followed by the transfection, the
cells were harvested and the surface expression of Jagged1 was measured by flow
cytometry (Figure 9A and Figure 9C). Western blot was performed to assess the
efficiency of HER2 knockdown (Figure 9B and Figure 9D). Similar to pharmacologic
inhibition of HER2, genetic depletion of HER2 resulted in an increase in surface
expression of Jagged1, suggesting that HER2 restricts the surface expression of
Jagged1.
As HER2 inhibition led to an increase in the surface expression of Jagged1, we
wanted to test whether there was an increase in the Jagged1 mRNA and total Jagged1
protein. For this purpose, HCC1954 cells were treated for 4 days with 2 µM lapatinib
and real-time PCR, and Western blot was performed to detect the levels of Jagged1
mRNA and Jagged1 protein respectively. There was an increase in the Jagged1 mRNA
upon lapatinib mediated HER2 inhibition (Figure 10A). However, Jagged1 protein
decreased upon lapatinib treatment (Figure 10C). As lapatinib treatment affected the
levels of beta actin, Ponceau staining was also performed to ensure that the loading
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was even across the samples (Figure 10B). These results reveal that even though the
total protein is decreased, there is an increase in the surface levels of Jagged1 protein.
The results suggest that this might be a trafficking mediated event, causing either
decreased endocytosis of Jagged1 from the cell surface or enhanced recycling of
Jagged1 from the endosome onto the cell surface.
Aim 1 is based on the hypothesis that the increase in surface expression of
Jagged1 upon HER2 inhibition leads to an increase in the Notch signaling dependent
formation of CSCs.

VEHICLE

MDA-MB-453 (HER2+)

Figure 7: Lapatinib Effectively Inhibits Tyrosine Kinase Activity of HER2 in MDAMB-453 Cells.
MDA-MB-453 cells were treated with vehicle control i.e. DMSO/ 2 µM lapatinib for 4
days. To ensure that lapatinib is able to effectively inhibit the phosphorylation of HER2,
protein was harvested and western blot was performed to detect the phosphorylation of
HER2 (Tyr 1221/Tyr 1222), total HER2 and Beta actin. Beta actin was used as a
loading control.
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Figure 8: Pharmacological Inhibition of HER2 Increases the Surface Expression of
Jagged1.
Various breast cancer cell lines were treated with vehicle DMSO/ 2 µM lapatinib for 4
days and the surface expression of Jagged1 was measured by using flow cytometry.
(A) Flow cytometry analysis for Jagged1 surface expression in HCC1954 cells. The
picture is representative of three independent experiments. Similar study was performed
using MDA-MB-453 (B), MCF7 (C), and MCF7-HER2 cells (D).
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Figure 9: Genetic Inhibition of HER2 Increases the Surface Expression of
Jagged1.
HER2 was knocked down in MDA-MB-453 and HCC1954 cells and the effect of HER2
knockdown on Jagged1 surface expression was measured my flow cytometry.
(A) MDA-MB-453 cells and (C) HCC1954 cells were transfected with HER2/scrambled
control siRNA for 48 hours. The cells were then stained with Jagged1 and the surface
expression of Jagged1 was measured by flow cytometry. The picture is representative
of three independent experiments.
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(B) Representative total HER2 western blot showing the efficiency of HER2 knockdown
in MDA-MB-453 cells. Beta actin was used as a loading control. The experiment was
performed independently for three times.
(D) Similarly, the efficiency of HER2 knockdown in HCC1954 cells was determined.
HCC1954 (HER2+)

A.

B.

C.

Figure 10: Effect of Lapatinib Mediated HER2 Inhibition on mRNA and Protein
Levels of Jagged1.
HCC1954 cells were treated with 2 µM lapatinib for 4 days and the effect of lapatinib
treatment on the transcript and protein levels of Jagged1 was assessed by real-time
PCR and Western blot respectively.
(A) Followed by the lapatinib treatment, HCC1954 cells were harvested, RNA was
extracted, cDNA was synthesized, and real-time PCR was performed to detect the
transcript levels of Jagged1. Error bars represent S.D. and the statistical significance
was calculated using unpaired t test. GraphPad Prism was used for the analysis.
**p<0.01.
(B) To determine the effect of lapatinib treatment on the protein levels of Jagged1, the
cells were harvested and Western blot was performed. Beta actin was used as a
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loading control. Based on previously performed experiments, lapatinib treatment
affected the levels of Beta actin. Hence, Ponceau staining was also performed after the
transfer to ensure that the loading was even across the samples. Panel B shows even
loading between the samples as determined by Ponceau staining. The image is
representative of three independent experiments.
(C) Panel C shows the Western blot that was performed to detect the effect of lapatinib
treatment on the protein levels of Jagged1. Beta actin was used as a loading control.
The figure is representative of three independent experiments.
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Aim 1A-Determine Whether Jagged1-High Subpopulation Upon Lapatinib
Treatment Results in an Increase in the Formation of CSCs as Compared to
Jagged1-Low Subpopulation in the Absence of Lapatinib Treatment. CSCs Would
be Assessed by %MFE, Aldehyde Dehydrogenase Activity and the Levels of CD44
High/CD24 Low.
To assess whether the enrichment of Jagged1 on the cell surface was necessary
for the formation of CSCs, HCC1954 cells were treated with 2 µM lapatinib or vehicle
DMSO for 4 days. The cells were harvested after the treatment and stained for
Jagged1.The Jagged1 stained cells were sorted through the cell sorter. 20% of the cells
expressing the least Jagged1 (as determined by the bell-shaped curve) upon vehicle
treatment, and 20% of the cells expressing highest Jagged1 upon lapatinib treatment
were sorted. This kind of sort provided two extremes of Jagged1 levels – vehicle treated
Jagged1-low cells and lapatinib treated Jagged1-high cells. Propidium iodide (1 µg/ml)
was used during the sort to exclude the dead cells from the assay. Various markers of
CSCs, i.e. mammosphere formation, levels of aldehyde dehydrogenase, and the levels
of CD44 high/CD24 low were assessed after the sort. These are the classic CSC
markers that are routinely used in the field of breast cancer.
Jagged1-high subpopulation shows enhanced mammosphere formation
upon HER2 inhibition, as compared to Jagged1-low subpopulation in the
absence of HER2 inhibition. To determine the effect of Jagged1 surface
expression on the formation of mammospheres, 35,000 vehicle Jagged1-low and
lapatinib Jagged1-high cells were sorted into 24 well ultra-low attachment plates
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containing mammosphere medium supplemented with or without 5 µM GSI (Figure
11A). The mammosphere formation was assessed after 7 days and representative
prictures were taken. The pictures are indicative of three independent experiments
(Figure 11B). The mammopsheres were then harvested and the mammopshere forming
efficiency was determined. The results revealed a significant increase in mammosphere
formation efficiency by the Jagged1-high cells as compared to Jagged1-low cells. The
addition of GSI to the mammosphere medium prevented the mammosphere formation,
confirming that the formation of mammospheres was dependent on Notch activation
(Figure 11C). The difference in mammosphere formation between vehicle treated
Jagged1-low cells and lapatinib treated Jagged1-high cells was more striking than the
difference observed when vehicle and lapatinib treated unsorted cells were used for the
mammosphere formation, implying that the surface expression of Jagged1 is required
for the formation of mammospheres and thus survival of CSCs.
A control experiment was performed to address whether higher Jagged1 surface
expression independent of HER2 inhibition was necessary to form mammospheres, and
thus CSCs. To test this, untreated HCC1954 cells were harvested and were stained for
surface Jagged1. 20% of the cells that express the least Jagged1 and 20% of the cells
that express the highest Jagged1 on the cell surface were sorted into mammosphere
plates containing mammosphere medium supplemented with or without 5 µM GSI
(Figure 12A). Mammosphere formation was assessed and pictures were taken after 7
days. The pictures are indicative of three independent experiments (Figure 12B). No to
little mammospheres were observed under Jagged1-high or Jagged1-low conditions,
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and GSI completely prevented mammosphere formation (Figure 12C). These results
suggest that both HER2 inhibition and increase in Jagged1 are necessary to enhance
mammosphere formation. Importantly, these results also suggest that the inherently
Jagged1-high cell population in HER2+ breast cancer cells might not be sufficient to
enhance mammosphere formation.
Jagged1-high subpopulation upon HER2 inhibition shows an enhancement
of aldehyde dehydrogenase positive CSCs, as compared to Jagged1-low
subpopulation in the absence of HER2 inhibition. To assess the effect of
Jagged1 surface expression on the levels of ALDH positive CSCs, vehicle treated
Jagged1-low and lapatinib treated Jagged1-high cells were sorted into FACS tubes.
Aldefluor assay was performed after cell sorting. MDA-MB-231 cells (Triple Negative
breast cancer cells) were used as a negative control (Figure 13A) and MDA-MB-468
cells (Triple Negative breast cancer cells) were used as a positive control for the assay
(Figure 13B). Jagged1-high cells from lapatinib treatment showed significantly higher
levels of ALDH, as compared to vehicle treated, Jagged1-low cells (Figure 13C-E). This
contrasts with what was observed for the unsorted cells, as lapatinib treatment reduced
ALDH levels in unsorted cells, although the decrease was not significant (Figure 14AC). These results signify the importance of the surface expression of Jagged1 for the
formation of ALDH positive CSCs.
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Upon HER2 inhibition, Jagged1-high subpopulation doesn’t show a
significant change in the levels of CD44 high/CD24 low CSCs, as compared
to Jagged1-low subpopulation in the absence of HER2 inhibition. To
determine whether lapatinib treatment which resulted in high Jagged1 surface
expression affected levels of CD44/CD24, vehicle treated Jagged1-low and lapatinib
treated Jagged1-high cells were sorted, stained with CD44 and CD24 antibodies, and
assessed by flow cytometry (Figure 15D-E). MDA-MB-231 cells were used as a positive
control (Figure 15B) and MDA-MB-468 cells served as a negative control (Figure 15C)
for the assay. Vehicle treated Jagged1-low cells had a very small fraction of CD44
high/CD24 low cells, which was further reduced in lapatinib treated Jagged1-high cells.
Similar results were observed when the assay was performed using unsorted cells
(Figure 16A-C). These results would imply that HER2 inhibition mediated increase in
Jagged1 surface expression does not enrich CSCs that express CD44 high/CD24 low.
The discrepancy observed between the two CSC markers could be attributed to
a recent report which shows that ALDH is a better marker for epithelial like CSCs, and
CD44 high/CD24 low is a better marker for mesenchymal-like CSCs (Liu, Cong et al.
2014). This would imply that by inhibiting HER2, we have enriched a subpopulation of
epithelial like CSCs that have higher Jagged1 on the cell surface.
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Figure 11: Jagged1-High Subpopulation Upon HER2 Inhibition Shows Enhanced
Mammosphere Formation.
(A) HCC1954 cells were treated with 2 µM lapatinib for 4 days. Followed by the

treatment, the cells were stained with Jagged1. The stained cells were sorted such that
- 20% of the cells that expressed least Jagged1 on the cell surface under vehicle
condition and 20% of the cells that expressed highest Jagged1 upon lapatinib treatment
were included (as shown above).
(B) 35,000 cells were sorted into mammosphere plates containing mammosphere
media supplemented with or without 5 µM GSI. The mammosphere pictures were taken
after 7 days and are representative of three independent experiments.
(C) Mammopshere were harvested after 7 days and the %MFE was determined. The
columns represent the average %MFE and the error bars represent the S.D. of three
independent experiments. The statistical significance was calculated using ANOVA for
multiple comparisons. GraphPad Prism was used for the analysis. * p<0.05, **p<0.01,
*** p<0.001, ****p<0.0001.
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Figure 12: Jagged1-High Subpopulation Without HER2 Inhibition Doesn’t Show
Enhanced Mammosphere Formation.
(A) HCC1954 cells were harvested and stained with Jagged1. The stained cells were
sorted such that - 20% of the cells that expressed least Jagged1 on the cell surface
under vehicle condition and 20% of the cells that expressed highest Jagged1 upon
lapatinib treatment were included (as shown above).
(B) 25,000 cells were sorted into mammosphere plates containing mammosphere
media supplemented with or without 5 µM GSI. The mammosphere pictures were taken
at the end of 7 days, and are representative of three independent experiments.
(C) The mammospheres were harvested after 7 days and the %MFE was determined.
The columns represent average %MFE and the error bars represent the S.D. of three
independent experiments. The statistical significance was calculated using ANOVA for
multiple comparisons. GraphPad Prism was used for the analysis.

MDA-MB-231

VEHICLE

C. JAGGED1 LOW

B. MDA-MB-468

CONTROL
0.527%

CONTROL
1.28%

TEST
0.569%

TEST
97.3%

SSC

SSC

A.

D. LAPATINIB

JAGGED1 HIGH

CONTROL
0.0768%

CONTROL
0.271%

TEST
53.4%

TEST
86.8%

-

96

ALDH FITC
ALDH FITC
ALDEFLUO R ASSAY

E.

**

% A L D H P O S IT IV E C E L L S

100

80

60

40

20

0

V E H IC L E

L A P A T IN IB

JAG G ED 1

JAG G ED 1

LO W

H IG H

Figure 13: Jagged1-High Subpopulation Upon HER2 Inhibition Shows Increased
Levels of ALDH1 Positive CSCs.
(A-B) Aldefluor assay was performed to dectect the %ALDH1+ CSCs. DEAB was used
in the control sample to inhibit ALDH1 and it acted as a negative control. MDA-MB-231
and MDA-MB-468 cells were used as negative control and positive control respectively.
The pictures are representative of three independent experiments.
(C-D) HCC1954 cells were treated with 2 µM lapatinib for 4 days. Followed by the
treatment, the cells were stained with Jagged1. The stained cells were sorted such that
20% of the cells that expressed least Jagged1 on the cell surface under vehicle
condition and 20% of the cells that expressed highest Jagged1 upon lapatinib treatment
were included (as described before). 200,000 cells from each sample were used to
perform the aldefluor assay. The pictures are representative of three independent
experiments.
(E) The bar graph represents the average of three independent experiments. Error bars
represent S.D. and the statistical significance was calculated using unpaired t test.
GraphPad Prism was used for the analysis. * p<0.05, **p<0.01.
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Figure 14: Lapatinib Mediated HER2 Inhibition Does Not Significantly Affect the
Levels of ALDH1 Positive CSCs in Unsorted Cells.
(A and B) HCC1954 cells were treated with vehicle control i.e. DMSO or 2 µM lapatinib
for 4 days. Followed by the treatment, the cells were harvested and aldefluor assay was
performed, as described in the methods section. DEAB was used in the control sample
to inhibit ALDH1 and it acted as a negative control. 200,000 cells from each sample
were used to perform the assay. Values mentioned along with the dot plots indicate the
percentage of ALDH1+ population. The pictures are representative of three independent
experiments
(C) The bar graph represents the average and the error bars represent S.D. of three
independent experiments. The statistical significance was calculated using unpaired t
test. GraphPad Prism was used for the analysis.
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Figure 15: Jagged1-High Subpopulation Upon HER2 Inhibition Does Not Show a
Marked Difference in the Levels of CD44 High/ CD24 Low CSCs.
HCC1954 cells were treated with 2 µM lapatinib for 4 days. Followed by the treatment,
the cells were stained with Jagged1. The stained cells were sorted such that- 20% of
the cells that expressed least Jagged1 on the cell surface under vehicle condition and
20% of the cells that expressed highest Jagged1 upon lapatinib treatment were included
(as described before). Followed by the sort, the cells were stained with CD44-FITC and
CD24-PE. Appropriate compensation controls were used and flow cytometry was
performed to detect the levels of CD44 high/CD24 low. The pictures are representative
of three independent experiments.
(A) Unstained Control
(B-E) Surface expression of CD44 and CD24, as assessed by flow cytometry. MDA-MB231 cells were used as a positive control and MDA-MB-468 cells were used as a
negative control.
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Figure 16: Lapatinib Mediated HER2 Inhibition Does Not Significantly Affect the
Levels of CD44 High/CD24 Low CSCs in Unsorted Cells.
HCC1954 cells were treated with 2 µM lapatinib for 4 days. The cells were stained with
CD44-APC and CD24-PE after the treatment, and flow cytometry was performed to
detect the levels of CD44 high/CD24 low. The pictures are representative of three
independent experiments.
(A) Unstained control.
(B and C) Surface expression of CD44 and CD24 when HCC1954 cells are treated with
vehicle control i.e. DMSO or lapatinib for 4 days.
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Aim 1B-Assess Whether Jagged1 is Necessary for Lapatinib Mediated
Enrichment of Mammospheres in the HER2+ Subtype of Breast Cancer.
Since the results indicated that HER2 inhibition results in an increase in Jagged1
expression on the cell surface, and that the subpopulation of cells expressing higher
Jagged1 on the cell surface is enriched with CSCs, we wanted to determine if Jagged1
was required for this effect.
Jagged1 is necessary for lapatinib mediated enrichment of
mammospheres. Jagged1 knockdown using siRNA was used to determine
whether Jagged1 expression is necessary for the HER2 inhibition-mediated enrichment
of mammospheres. In order to ensure specificity and rule out the possibility of any offtarget effects, two different siRNAs directed against Jagged1 were used. The cells were
harvested and replated after transfection. The next day they were treated with vehicle
DMSO or 2 µM lapatinib. The treatment was performed for 4 days. A second
transfection was performed after 2 days of treatment to ensure that the transient
knockdown lasts for 4 days of treatment. Protein was harvested at the end of 4 days
and Western blot was performed to assess the efficiency of the Jagged1 knockdown.
Beta actin was used as a loading control. Both the siRNAs were able to effectively
knock down Jagged1 at the protein level (Figure 17A). The cells were harvested after
treatment and 100,000 individual cells were plated into each well of a 6 well
mammosphere plate containing mammosphere media. Mammospheres were harvested
after 7 days and the %MFE under each condition was determined.
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Under the scrambled control conditions, lapatinib treatment resulted in an
enrichment of mammospheres. However, upon Jagged1 knockdown, lapatinib treatment
failed to increase mammosphere formation. Jagged1 knockdown without lapatinib
treatment did not significantly reduce mammosphere formation (Figure 17B-E). These
results suggest that when HER2 is inhibited, Jagged1 enriched subpopulation of cells is
required for the formation of the mammospheres, and thus survival of CSCs.
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Figure 17: Jagged1 Is Necessary for Lapatinib Mediated Enrichment of
Mammospheres.
(A) HCC1954 cells were transfected with non-targeted scrambled control siRNA or
Jagged1 siRNA for 48 hours. To rule out the possibility of any off-target effect of siRNA,
two different sequences of siRNA targeting Jagged1 were used (Jagged1 A and
Jagged1 B). Followed by the transfection, the cells were treated for 4 days with vehicle
DMSO or 2 µM lapatinib. The second transfection was performed after 2 days of
treatment to ensure that the transient transfection lasts until 4 days. The cells were
harvested after treatment and Jagged1 knockdown was determined by western blot.
Beta actin was used as a loading control.
(B, D) For the mammosphere assay, the cells were harvested after the treatment, and
100,000 single cells were plated into 6 well ultra-low attachment plate containing
mammosphere media. The mammospheres were harvested after 7 days and the
mammosphere pictures were taken. The pictures are representative of three
independent experiments.
(C, E) The mammospheres were harvested after 7 days and the %MFE under each
condition was determined. The mammosphere images are representative of three
independent experiments. Error bars represent S.D. and the statistical significance was
calculated using ANOVA for multiple comparisons. GraphPad Prism was used for the
analysis. * p<0.05, **p<0.01.
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Aim 1C-Measure the Degree of Notch Activation in Jagged1-High Subpopulation
upon Lapatinib Treatment and in the Jagged1-Low Subpopulation in the Absence
of Lapatinib Treatment.
Previous work by Osipo et al. demonstrated that HER2 inhibition results in an
increase in Notch activation (Osipo, Patel et al. 2008). Since HER2 inhibition resulted in
an increase in membrane Jagged1 expression, we wanted to test the status of Notch
activation in the subset of cells that expressed high membrane Jagged1.
The Jagged1-high subpopulation in the presence of lapatinib mediated
HER2 inhibition has higher Notch activation, as compared to the Jagged1low subpopulation, in the absence of HER2 inhibition. To assess the Notch
activation in the Jagged1-high subpopulation, HCC1954 cells were treated with 2 µM
lapatinib for 4 days and then the cells were sorted based on Jagged1 membrane
expression. Followed by this, the RNA was extracted using QIAGEN RNeasy micro kit.
The extracted RNA was quantified and cDNA was synthesized using reverse
transcription. Real-time PCR was performed to detect Notch activation by using primers
directed against the Notch target gene transcripts. Jagged1- high subpopulation of cells
in response to lapatinib showed a significant increase in the transcript levels of most
Notch targets (Hes1, Hes4, Hey2, CyclinD1, and c-Myc), as compared to vehicle
treated, Jagged1-low subpopulation (Figure 18A-F). Upon HER2 inhibition, significant
Notch activation was observed in unsorted cells as well (Hes1) (Figure 19).
Besides Notch targets, the transcript levels of Notch receptors were measured in
the two subpopulations as well. Upon HER2 inhibition, the Jagged1-high subpopulation
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showed a significant increase in the expression of Notch1 and Notch3 receptors, as
compared to the Jagged1-low subpopulation in the absence of HER2 inhibition. The
expression of Notch2 and Notch4 receptors also increased in the Jagged1-high
subpopulation. However, the increase was not significant (Figure 20). The expression
of the Notch2 receptor was the lowest, and hence the relative fold change in the
expression of all other receptors was normalized against vehicle/-Jagged1-low-Notch2.
As mentioned before, Notch signaling functions in a contact dependent manner.
To our surprise, the ligand expressing cells showed higher Notch activation. The Notch
receptor is activated by the ligand on the signal sending cell. However, if the Notch
receptor and the Notch ligand are present on the same cell, then it leads to inhibition of
Notch signaling, and this phenomenon is known as cis inhibition (del Alamo, Rouault et
al. 2011). To address this, we performed flow cytometry to detect the surface
expression of Notch receptors (Notch1, Notch3, and Notch4). Since Notch2 was the
least expressed and was barely detected by real-time PCR, Notch2 was not used for
any further investigation. The results revealed that all the cells that express Jagged1 on
the membrane also express Notch1 (Figure 21B-C), Notch3 (Figure 21D-E), and Notch4
(Figure 21F-G) on the surface. This suggests that HER2 inhibition selects for a
subpopulation of cells that have high membrane Jagged1, as well as Notch receptors
on the surface and that Jagged1 on the membrane of one cell could interact with Notch
receptor on another cell within the same subpopulation.
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Figure 18: Jagged1-High Subpopulation in the Presence of Lapatinib Mediated
HER2 Inhibition Has Higher Notch Activation, as Compared to Jagged1-Low
Subpopulation in the Absence of HER2 Inhibition.
HCC1954 cells were treated with 2 µM lapatinib for 4 days. Followed by the treatment,
the cells were stained with Jagged1. The stained cells were sorted such that - 20% of
the cells that expressed least Jagged1 on the cell surface under vehicle control
condition i.e. DMSO and 20% of the cells that expressed highest Jagged1 upon
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lapatinib treatment (LAP) were included (as described before). RNA was extracted from
the sorted cells using QIAGEN RNeasy Micro kit. cDNA was synthesized from the
extracted RNA and real- time PCR was performed to detect the transcript levels of
Notch target genes.
(A) HES1 (B) HES4 (C) CYCLIND1 (D) c-MYC (E) HEY2 and (F) HEY1. HPRT was
used as an endogenous control. Columns represent the average gene expression
(normalized to HPRT) and the error bars represent S.D. of three independent
experiments. The statistical significance was calculated using unpaired t test. GraphPad
Prism was used for the analysis. * p<0.05, **p<0.01, ***p<0.001.

Figure 19: HER2 Inhibition Results in an Increase in Notch Activation.
HCC1954 cells were treated for 4 days with vehicle DMSO or 2 µM lapatinib. Followed
by the drug treatment, the cells were harvested and real-time PCR was performed to
detect the transcript levels of Notch targets. The graph above shows HES1 levels under
the two conditions. HPRT was used as endogenous control. Columns represent the
average gene expression (normalized to HPRT) and the error bars represent S.D.. The
statistical significance was calculated using unpaired t test. GraphPad Prism was used
for the analysis. * p<0.05.
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Figure 20: Jagged1-High Subpopulation Has Increased Expression of Notch1 And
Notch3 Receptors.
HCC1954 cells were treated with 2 µM lapatinib for 4 days. Followed by the treatment,
the cells were stained with Jagged1. The stained cells were sorted such that - 20% of
the cells that expressed least Jagged1 on the cell surface under vehicle condition and
20% of the cells that expressed highest Jagged1 upon lapatinib treatment were included
(as described before). Followed by the sort, RNA was extracted from the cells using
QIAGEN RNeasy Micro kit. cDNA was synthesized from the extracted RNA and realtime PCR was performed to detect the transcript levels of Notch target genes. HPRT
was used as an endogenous control. Real-time PCR results show means of fold
changes between the two subpopulations, normalized against vehicle Jagged1-lowNotch2. Error bars represent S.D. and the statistical significance was calculated using
unpaired t test. GraphPad Prism was used for the analysis. * p<0.05, **p<0.01.
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Figure 21: Jagged1 Is Co-Expressed Along with Notch1, Notch3, And Notch4.
HCC1954 cells were treated with vehicle control DMSO or 2 µM lapatinib for 4 days.
Followed by the drug treatment, the cells were harvested and were divided into 3 sets of
tubes and were stained accordinglyI Jagged1 and Notch1 staining II Jagged1 and Notch3 staining III Jagged1 and Notch4
staining. Followed by the staining, the surface expression of Jagged1 and the Notch
receptors with or without the lapatinib treatment was assessed by flow cytometry.
Appropriate compensation controls were used. The pictures are representative of three
independent experiments.
(A) Unstained Control
(B) Vehicle-Jagged1+Notch1
(D) Vehicle-Jagged1+Notch3
(F) Vehicle-Jagged1+Notch4

(C) Lapatinib-Jagged1+Notch1
(E) Lapatinib-Jagged1+Notch3
(G) Lapatinib-Jagged1+Notch4
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Aim 1D-Identify the Notch Receptor That Interacts with Jagged1 to Cause
Lapatinib Mediated Enrichment of Mammospheres in the HER2+ Subtype of
Breast Cancer.
As Notch signaling works in a contact dependent fashion, we wanted to
determine the Notch receptor that Jagged1 engages with, to mediate Notch signaling.
Based on the real-time PCR data, mRNA levels of all the Notch receptors were
increased in the Jagged1-high subpopulation, the levels of Notch1 and Notch3 being
significantly high in the Jagged1-high subpopulation. Flow cytometry data showed that
Jagged1 is co-expressed with Notch1, Notch3, and Notch4. Jagged1 could interact with
one or multiple Notch receptors to mediate Notch activation and enhance formation of
CSCs. There have been reports elucidating the involvement of Notch1, Notch3, and
Notch4 receptors in the formation of breast CSCs (Sansone, Storci et al. 2007,
Magnifico, Albano et al. 2009, Harrison, Farnie et al. 2010).
The question that we asked was: Which receptor is required in the engagement
with Jagged1 to mediate lapatinib induced enrichment of mammospheres, and thus
CSCs? To address this question, HCC1954 cells were transfected with scrambled
control siRNA or the siRNA targeted against Notch1, Notch3, or Notch4 individually for
48 hours. Followed by the transfection, the cells were treated with vehicle control or 2
µM lapatinib for four days. A second transfection was performed after two days, to
ensure that the transient transfection lasts until four days of treatment. Followed by the
treatment, the knockdown was assessed by either Western blot or flow cytometry.
Notch3 knockdown was detected by Western blot. Beta actin was used as a loading
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control (Figure 22 A). To assess Notch1 knockdown (Figure 23 A-B) and Notch4
knockdown (Figure 24 A-B), flow cytometry was performed as the signal by Western
blot was weak and non-specific.
For performing mammosphere assay, the cells were harvested after the
treatment, and 100,000 individual cells were plated in a 6 well ultra-low attachment plate
containing mammosphere media. The mammospheres were harvested after 7 days and
the %MFE was determined under each condition.
In agreement with previous data, we saw lapatinib mediated enrichment of
mammospheres under control conditions. Notch3 knockdown significantly increased
mammosphere formation as compared to scrambled control in the absence of lapatinib
treatment. Notch3 knockdown showed no significant change in the mammosphere
formation as compared to scrambled knockdown in the presence of lapatinib treatment
(Figure 22 C).
Notch1 knockdown did not significantly affect the mammosphere formation under
control or lapatinib treated conditions (Figure 23 D). Notch4 knockdown did not show
any effect on the mammosphere formation under control or lapatinib treated conditions
(Figure 24 D). Based on the Western blot and flow cytometry data, the knockdown of
Notch1 and Notch4 was not efficient. Hence, it is hard to conclude anything regarding
the role of Notch1 and Notch4 receptors in the lapatinib mediated enrichment of
mammospheres. Future investigation should involve creating stable cell lines using the
CRISPR approach to effectively knockout Notch1 and Notch4. The stable cell lines can
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then be used to test the role of Notch1 and Notch4 in mediating lapatinib mediated
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Figure 22: Effect of Notch3 Knockdown on the Lapatinib Mediated Enrichment of
Mammospheres.
(A) HCC1954 cells were transfected with non-targeted scrambled control siRNA or
Notch3 siRNA for 48 hours. After the transfection, the cells were treated for 4 days with
vehicle DMSO or 2 µM lapatinib. Followed by the treatment, the cells were harvested
and Notch3 knockdown was determined by western blot. Beta actin was used as a
loading control.
(B) For the mammosphere assay, the cells were harvested after the treatment, and
100,000 single cells were plated into 6 well ultra-low attachment plate containing
mammosphere media. At the end of 7 days, the mammopshere pictures were taken.
The pictures are representative of three independent experiments.
(C) The mammospheres were harvested after 7 days and the %MFE under each
condition was determined. The columns represent the average %MFE and the error
bars represent S.D. of three independent experiments. The statistical significance was
calculated using ANOVA for multiple comparisons. GraphPad Prism was used for the
analysis. * p<0.05
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Figure 23: Effect of Notch1 Knockdown on the Lapatinib Mediated Enrichment of
Mammospheres.
HCC1954 cells were transfected with non-targeted scrambled control siRNA or Notch1
siRNA for 48 hours. After the transfection, the cells were treated for 4 days with vehicle
DMSO or 2 µM lapatinib. The cells were harvested after the treatment and Notch1
knockdown was determined by western blot (A) or flow cytometry (B). Beta actin was
used as a loading control for western blot.
(C) For the mammosphere assay, the cells were harvested after the treatment, and
100,000 single cells were plated into 6 well ultra-low attachment plate containing
mammosphere media. At the end of 7 days, the mammosphere pictures were taken.
The pictures are representative of three independent experiments.
(D) The mammospheres were harvested after 7 days and the %MFE under each
condition was determined. The columns represent the average %MFE and the error
bars represent the S.D. of three independent experiments. The statistical significance
was calculated using ANOVA for multiple comparisons. GraphPad Prism was used for
the analysis. * p<0.05
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Figure 24: Effect of Notch4 Knockdown on the Lapatinib Mediated Enrichment of
Mammospheres.
HCC1954 cells were transfected with non-targeted scrambled control siRNA or Notch4
siRNA for 48 hours. After the transfection, the cells were treated for 4 days with vehicle
DMSO or 2 µM lapatinib. The cells were harvested after the treatment and Notch4
knockdown was determined by western blot (A) or flow cytometry (B). Beta actin was
used as a loading control for western blot.
(C) For the mammosphere assay, the cells were harvested after the treatment, and
100,000 single cells were plated into 6 well ultra-low attachment plate containing
mammosphere media. At the end of 7 days, the mammosphere pictures were taken.
The pictures are representative of two independent experiments.
(D) The mammospheres were harvested after 7 days and the %MFE under each
condition was determined. The columns represent the average %MFE and the error
bars represent the S.D. of two independent experiments. GraphPad Prism was used for
plotting the graph.
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Specific Aim 2- Assess the Ability of Jagged1-High Subpopulation to Form a
Tumor In Vivo and to Measure its CSC Potential
As mentioned before, another name for CSC is TIC. Hence, the true assessment
of CSC relies on the ability of the cells to form a tumor in vivo. It is done by using
limiting dilution assay, which is considered as a gold standard in the breast cancer field
for the assessment of true CSC frequency. It involves using log fold dilution of the cell
population and determining tumor take at each dilution. The idea is that if the cell
population is truly enriched with CSCs, it’ll have a higher CSC frequency and the ability
to form the tumor with a lower cell number. Researchers have used as low as 10 cells
for the assessment of CSC frequency (Cheung, Chuang et al. 2016). Using bulk tumor
cells, 1-10 million cells are required to form the tumor.
Based on our in vitro data, HER2 inhibition enriches for a Jagged1-high
subpopulation of cells that have increased capacity to form mammospheres and have
enhanced aldefluor activity. Moreover, Jagged1 was found to be necessary for the
enrichment of CSCs when HER2 was inhibited. To determine if the Jagged1-high
subpopulation is indeed enriched with CSCs, we performed a pilot in vivo experiment
using 10,000 cells sorted on the basis of Jagged1 surface expression.
Jagged1-high subpopulation shows 100 percent tumor take in vivo with
10,000 sorted cells. For the in vivo study, HCC1954 cells were treated with
vehicle or 2 µM lapatinib. After the treatment, the cells were harvested, stained, and
were sorted for Jagged1 surface expression, as mentioned before. Followed by sorting,
10,000 cells were diluted in PBS and mixed with Matrigel (1:1 ratio). The cell
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suspension was then injected into the mammary fat pad of ovariectomized FoxN1 nu/nu
athymic nude mice. The mice were monitored weekly for tumor take in each group
(tumors ≥ 40 mm2 were considered palpable and measured). The experiment was
continued for up to 10 weeks. Based on tumor take, a Kaplan Meier curve for % tumor
free mice was plotted. The group of mice that were injected with 10,000 lapatinib treated
Jagged1-high cells showed 100 percent tumor take (5/5) i.e. zero percent tumor free
mice. The group that was injected with 10,000 vehicle treated Jagged1-low cells
showed 33.3 percent tumor take (2/6) i.e. 66.6 percent tumor free mice. The difference
in the tumor take between the two groups was found to be statistically significant, as
determined by the Log-rank (Mantel-Cox) Test (P = 0.0051) (Figure 25).
Normally, 1-2.5 million HCC1954 cells are injected into the mammary fat pad for
in-vivo studies. These results of the study suggested that Jagged1-high subpopulation
of cells were enriched with CSCs, as 100 percent tumor take was observed with as few
as 10,000 Jagged1-high sorted cells.
Jagged1-high subpopulation has significantly higher CSC frequency as
compared to the Jagged1-low subpopulation, and Jagged1 neutralizing
antibody did not reduce the CSC frequency of either subpopulation. The
pilot study convincingly showed that upon HER2 inhibition, the Jagged1-high
subpopulation is indeed enriched with CSCs. To determine the CSC frequency of the
Jagged1-high and Jagged1-low subpopulations, limiting dilution assay was performed in
vivo. Also, the effect of blocking Jagged1 on CSC frequency of both the subpopulations
was assessed by using a neutralizing antibody against Jagged1 (CTX-014). HCC1954
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cells were sorted based on the membrane expression of Jagged1 i.e. vehicle treated
Jagged1-low subpopulation and lapatinib treated Jagged1-high subpopulation. Followed
by sorting, either 100, 1000 or 10,000 cells were injected into the mammary fat pad of
ovariectomized athymic nude mice and tumor take was assessed up to 8 weeks (tumors
≥ 40 mm2 were considered palpable and measured). One week after injecting the cells,
the mice were randomized into control (Figure 26 A-B) and Jagged1 neutralizing
antibody (CTX-014) treatment groups (Figure 26 C-D). 10 mg/kg CTX-014 or PBS
control was injected intraperitoneally (i.p.) once a week. The antibody acts by
preventing the binding of Jagged1 and Jagged2 with Notch receptors. There were four
groups of each dilution of 100, 1000 and 10,000 cellsi. Vehicle Jagged1-low control
ii. Vehicle Jagged1-low CTX-014
iii. Lapatinib Jagged1-high control
iv. Lapatinib Jagged1-high CTX-014
Based on the tumor take in each group, the CSC frequency was calculated using ELDA
software (Table 6).
The results from ELDA revealed that the Jagged1-high subpopulation after
lapatinib treatment had significantly higher CSC frequency (1/2180, p-value=0.000413)
as compared to vehicle treated Jagged1-low subpopulation (1/12638). Interestingly,
CTX-014 treatment significantly increased the CSC frequency of vehicle Jagged1-low
subpopulation (1/3279, p-value=0.0166). CTX-014 did not significantly affect the CSC
frequency of the lapatinib Jagged1-high subpopulation (1/3357, p value 0.377). The in

121

vivo results conclusively demonstrated the high tumor initiating potential of the Jagged1high subpopulation after HER2 inhibition.
Also, average tumor area and average tumor weight assessment of the groups at
each dilution i.e. 100 cells, 1000 cells and 10,000 cells was performed. A line graph of
number of cells injected versus average tumor area (Figure 27) or number of cells
injected versus average tumor weight (Figure 28) was plotted for each group. However,
there was high variation in the tumor size within each group at each dilution. Due to very
high S.D. amongst the samples within each group, no significant difference in average
tumor area or average tumor weight was observed between the groups.
The Jagged1 neutralizing antibody (CTX-014) was not found to be effective, and
it significantly increased the CSC frequency of the vehicle, Jagged1-low subpopulation.
This could be attributed to suboptimal binding of the antibody to Jagged1 or rapid
clearance of the antibody from the murine immune system. Development of antibodies
against CTX-014 or clonal selection of Jagged1-low cells by CTX-014 treatment are
other possible reasons for the ineffectiveness of the CTX-014 antibody.
Higher Jagged1 surface expression predicts poor overall survival in
women suffering from HER2+ breast cancer. To assess the importance of
membrane Jagged1 on survival of women with HER2+ breast cancer, we examined the
University of Nottingham breast cancer cohort, prepared as tissue microarray. 145
HER2+ breast cancer tissues were stained for Jagged1 and assessed for outcome
based on Kaplan-Meier analysis. Based on the staining intensity, the samples were
classified into different groups, high Jagged1 (membrane/cytoplasmic/nuclear: staining
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intensity 2-3) or low Jagged1 (membrane/cytoplasmic/nuclear: staining intensity 0-1)
(Figure 29A-D). The cumulative survival of each patient was assessed. The cumulative
survival was defined as the time from the onset of surgery to breast cancer related
death. The results revealed that there was no significant correlation between
cytoplasmic or nuclear Jagged1 (Figure 29F-G) and the overall cumulative survival (logrank P = 0.186 for nuclear Jagged1 and log-rank P=0.914 for cytoplasmic Jagged1).
However, there was a significant inverse correlation between membrane Jagged1
staining and overall cumulative survival i.e. higher Jagged1 on the membrane
significantly predicted poor overall survival in women with HER2+ breast cancer (logrank P=0.01) (Figure 29E). Table 7 depicts the case processing summary for membrane
Jagged1 (Table 7A), nuclear Jagged1 (Table 7B), and cytoplasmic Jagged1 (Table 7C).

Figure 25: Jagged1-High Subpopulation Has Higher CSC Potential (Pilot
Experiment).
To assess the ability of Jagged1-high subpopulation to form tumors, vehicle treated
Jagged1-low cells and lapatinib treated Jagged1-high cells were sorted, as described
before. 10,000 sorted cells were resuspended into matrigel (1:1 matrigel:PBS) and were
then injected into mammary fat pad of athymic nude mice, and tumor take was
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assessed for up to 10 weeks. Based on the tumor take, Kaplan-Meier curve was plotted
and the statistics were performed using Log-rank (Mantel-Cox) test.
B.

A.

C.

D.

124

Figure 26: Jagged1-High Subpopulation Has Higher CSC Potential.
To assess the true CSC potential of the Jagged1-high subpopulation, vehicle Jagged1low subpopulation and lapatinib treated Jagged1-high subpopulation of cells were
sorted, as described before. Followed by the sort, 10,000, 1,000 or 100 cells were
resuspended into matrigel (1:1 matrigel:PBS) and injected into mammary fat pad of
athymic nude mice. The tumor take was assessed for each dilution of cells for 8 weeks
and tumors ≥ 40 mm2 were considered for the CSC frequency estimate. To determine
the effect of Jagged1 on CSC frequency, the mice were randomized for control or
Jagged1 neutralizing antibody (CTX-014) treatment. The treatment was started after
one week of injecting the cells. There were four groups of each dilution of 100, 1000
and 10,000 cells- i vehicle Jagged1-low-control, ii vehicle Jagged1-low-CTX-014, iii
lapatinib Jagged1-high-control, iv lapatinib Jagged1-high-CTX-014. CSC frequency was
calculated using ELDA software.
The above figure shows the representative images of mice and tumors from the vehicle
Jagged1-low-control (A), lapatinib Jagged1-high-control (B), vehicle Jagged1-low-CTX014 (C), and lapatinib Jagged1-high-CTX-014 (D).
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Table 6: Impact of Jagged1 Neutralizing Antibody (CTX-014) on the CSC
Frequency Estimate of the Jagged1 Subpopulations.
To assess the true CSC potential of the Jagged1-high subpopulation, vehicle Jagged1low subpopulation and lapatinib treated Jagged1-high subpopulation of cells were sorted,
as described before. Followed by the sort, 10,000, 1,000 or 100 cells were resuspended
into matrigel (1:1 matrigel:PBS) and injected into mammary fat pad of athymic nude mice.
The tumor take was assessed for each dilution of cells for 8 weeks and tumors ≥ 40 mm 2
were considered for the CSC frequency estimate. To determine the effect of Jagged1 on
CSC frequency, the mice were randomized for control or Jagged1 neutralizing antibody
(CTX-014) treatment. The treatment was started after one week of injecting the cells.
There were four groups of each dilution of 100, 1000 and 10,000 cells- i Vehicle Jagged1low-control, ii Vehicle Jagged1-low-CTX-014, iii Lapatinib Jagged1-high-control, iv
Lapatinib Jagged1-high-CTX-014. CSC frequency was calculated using ELDA software.
The table reveals the CSC frequency estimate calculated using ELDA software.
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Figure 27: Effect of Jagged1 Neutralizing Antibody (CTX-014) on the Average
Tumor Area of the Jagged1 Subpopulations at Different Dilutions.
To assess the true CSC potential of the Jagged1-high subpopulation, vehicle Jagged1low subpopulation and lapatinib treated Jagged1-high subpopulation of cells were
sorted, as described before. Followed by the sort, 10,000, 1,000 or 100 cells were
resuspended into matrigel (1:1 matrigel:PBS) and injected into mammary fat pad of
athymic nude mice. The tumor take was assessed for each dilution of cells for 8 weeks
and tumors ≥ 40 mm2 were considered for the CSC frequency estimate. To determine
the effect of Jagged1 on CSC frequency, the mice were randomized for control or
Jagged1 neutralizing antibody (CTX-014) treatment. The treatment was started after
one week of injecting the cells. There were four groups of each dilution of 100, 1000
and 10,000 cells- i Vehicle Jagged1-low – control, ii Vehicle Jagged1-low-CTX-014, iii
Lapatinib Jagged1-high-control, iv Lapatinib Jagged1-high-CTX-014. The average
tumor area was calculated after 8 weeks for each group at different dilutions and the
graph of average tumor area versus number of cells injected was plotted. Error bars
represent S.D. and the statistical significance was calculated using ANOVA for multiple
comparisons. GraphPad Prism was used for the analysis. The graph was created using
MS-Excel.
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Figure 28: Effect of Jagged1 Neutralizing Antibody (CTX-014) on the Average
Tumor Weight of the Jagged1 Subpopulations at Different Dilutions.
To assess the true CSC potential of the Jagged1-high subpopulation, vehicle Jagged1low subpopulation and lapatinib treated Jagged1-high subpopulation of cells were
sorted, as described before. Followed by the sort, 10,000, 1,000 or 100 cells were
resuspended into matrigel (1:1 matrigel:PBS) and injected into mammary fat pad of
athymic nude mice. The tumor take was assessed for each dilution of cells for 8 weeks
and tumors ≥ 40 mm2 were considered for the CSC frequency estimate. To determine
the effect of Jagged1 on CSC frequency, the mice were randomized for control or
Jagged1 neutralizing antibody (CTX-014) treatment. The treatment was started after
one week of injecting the cells. There were four groups of each dilution of 100, 1000
and 10,000 cells- i Vehicle Jagged1-low-control, ii Vehicle Jagged1-low-CTX-014, iii
Lapatinib Jagged1-high-control, iv Lapatinib Jagged1-high-CTX-014. At the end of 8
weeks, average tumor weight was calculated for each group at different dilutions and
the graph of average tumor weight versus number of cells injected was plotted. Error
bars represent S.D. and the statistical significance was calculated using ANOVA for
multiple comparisons. GraphPad Prism was used for the analysis. The graph was
created using MS-Excel.

A.

E.

B.

C.

F.

128

D.

G.

Figure 29: Jagged1 Membrane Expression Predicts Poor Overall Survival in
Women with HER2+ Breast Cancer.
TMA was performed on Nottingham cohort of 145 HER2+ breast cancer tissues and
Jagged1 staining was performed. Jagged1 was found to be localized in the nucleus,
cytoplasm and cell membrane.
The panels are representative of negative staining (A), membrane staining (B),
cytoplasmic staining (B,C, and D), and nuclear staining (D).
The tissues were scored 0.0 for low/negative staining and 1.0 for high/positive staining.
Kaplan-Meier curve was plotted for overall survival and statistics was performed for
membrane Jagged1 (E), cytoplasmic Jagged1 (F), and nuclear Jagged1 (G) using logrank (Mantel-Cox) test.
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Table 7: Case Processing Summary and Overall Comparisons for the TMA
Analysis.
The study was performed on 145 HER2+ breast cancer tissues. The table depicts the
case processing summary for membrane Jagged1 (A), nuclear Jagged1 (B), and
cytoplasmic Jagged1 (C). Statistics was performed by using log rank (Mantel-Cox) test.

CHAPTER VI
DISCUSSION
HER2+ breast cancer accounts for about 20% of all breast cancer cases. Current
therapeutic regimen involves the use of anti-HER2 agents such as trastuzumab,
pertuzumab, T-DM1, or lapatinib in combination with chemotherapy. The first line
therapy for advanced, metastatic HER2+ breast cancer involves the combination of
trastuzumab and pertuzumab along with docetaxel. This combination therapy showed
less than 30% progression free survival and 57.6% overall survival at the end of four
years. The median duration of response was only 20.2 months (Swain, Baselga et al.
2015). Thus, there is a dire need for better therapeutic strategies for the treatment of
HER2+ breast cancer. One possible explanation for low response rate and drug
resistance could be the existence of low lying subpopulation of CSCs. Due to tumor
heterogeneity, the therapeutic regimen would be ineffective in targeting the CSCs which
would then repopulate the tumor and promote drug resistance.
In the context of HER2+ breast cancer, Magnifico et al. have reported that HER2
is overexpressed in CSCs as compared to the bulk cells and that trastuzumab could be
effectively used to target CSCs. Moreover, they showed that HER2 levels were
upregulated by Notch1 signaling (Magnifico, Albano et al. 2009). In contrast with
Magnifico’s work, another study has shown that CD44 high/ CD24 low CSC
subpopulation express lower levels of HER2 on the cell surface due to autophagy
mediated internalization of HER2 and so trastuzumab is not able to effectively target the
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CD44 high/ CD24 low tumorigenic subpopulation, as Natural Killer cells are unable to
target HER2 to cause ADCC (Diessner, Bruttel et al. 2014). Moreover, HER2 low
subpopulation sorted from mammospheres formed from the Luminal A subtype MCF7
cells had higher levels of CSC markers and CSC properties. The investigators found
that HER2 high subpopulation was affected by trastuzumab, however, CSC containing,
HER2 low subpopulation was not targeted by trastuzumab (Oak, Kopp et al. 2012).
Lack of targeting of the CSC subpopulation by trastuzumab would explain why the
response rate of single agent trastuzumab was only 26% (Vogel, Cobleigh et al. 2002).
Numerous signaling pathways have been implicated in the formation of CSCs. In
HER2+ breast cancer, we have shown before that HER2 restricts Notch1 activation and
that targeting HER2 results in the activation of Notch1 (Osipo, Patel et al. 2008). In an in
vivo model, our group has shown that combining a Notch inhibitor with anti-HER2
agents is effective in the prevention of tumor recurrence and partial reversal of drug
resistance (Pandya, Meeke et al. 2011). A recent study combining a mouse model of
recurrent tumorigenesis and bioinformatic analyses of patient samples showed that
Notch signaling is upregulated following HER2 inhibition, that Notch signaling remains
activated in the subset of dormant tumor cells that survive after HER2 downregulation,
that activation of Notch signaling accelerates tumor recurrence, and pharmacological
and genetic inhibition of Notch signaling is critical for the prevention of tumor recurrence
(Abravanel, Belka et al. 2015). This data suggest that the activation of Notch signaling
in the probable CSCs promotes breast tumor recurrence. Notch1 and Notch4 receptors
have been previously implicated in the formation of CSCs in HER2+ breast cancer
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(Magnifico, Albano et al. 2009, Harrison, Farnie et al. 2010). Higher expression of
Jagged1 and Notch1 mRNA is associated with overall survival of breast cancer patients
(Reedijk, Odorcic et al. 2005). We have previously shown that Jagged1 is necessary for
trastuzumab mediated Notch activation, that dual inhibition of HER2 and Jagged1
inhibits cell proliferation in vitro, and drug resistance in vivo (Pandya, Wyatt et al. 2016).
In the current study, we sought to investigate the role of Jagged1 in the formation of
CSCs in HER2+ breast cancer.
Preliminary results showed that HER2 restricts Jagged1 surface expression and
that pharmacologic or genetic inhibition of HER2 results in an increase in Jagged1 on
the cell surface (Figure 8 and Figure 9). Also, the increase in Jagged-1 membrane
expression is dependent on the amount of active HER2 and not total HER2. Lapatinib
would inhibit the tyrosine kinase activity but would increase the levels of total HER2 by
stabilizing HER2 on the surface (Scaltriti, Verma et al. 2009). The increase in Jagged-1
upon lapatinib treatment is related to reduced levels of active HER2. Moreover, lapatinib
mediated HER2 inhibition resulted in an increase in mammosphere formation
suggesting an increase in survival of CSCs. The mammosphere formation was
dependent on Notch activation as a GSI prevented or significantly reduced the
mammosphere formation. Since lapatinib is a dual HER2-EGFR tyrosine kinase
inhibitor, we wanted to confirm whether the effect that we observed was indeed due to
HER2 inhibition. To address this, MCF7 cells and MCF7 cells stably overexpressing
HER2 (MCF7-HER2) were treated with lapatinib. EGFR protein level is high in MCF7
cells, and they have very little HER2. On the other hand, MCF7-HER2 overexpress
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HER2. The results showed an increase in the Jagged1 surface expression and a
significant increase in the mammosphere formation upon lapatinib treatment in the
MCF7-HER2 cells, but not in MCF7 cells. These results suggest that lapatinib mediated
inhibition of HER2 tyrosine kinase activity is responsible for the increase in the Jagged1
surface expression and enrichment of mammospheres (Figure 6). Based on this
information, Aim 1 investigated whether HER2 inhibition resulted in a subpopulation that
had high Jagged1 on the cell surface and caused the formation of CSCs.
Results from Aim 1 showed that Jagged1-high subpopulation upon HER2
inhibition increased the formation of mammospheres and thus CSCs that is dependent
on Notch activation (Figure 11). Besides mammospheres, the Jagged1-high
subpopulation upon HER2 inhibition also had enhanced levels of aldehyde
dehydrogenase (which is another marker for CSCs) as compared to Jagged1-low
subpopulation in the absence of HER2 inhibition (Figure 13). The levels of CD44 high/
CD24 low (another marker for CSCs) did not change significantly between the two
subpopulations (Figure 15). Per the recent review from Dr. Max Wicha’s group, aldefluor
assay is a better indicator of epithelial-like CSCs and CD44 high/CD24 low is a better
indicator of mesenchymal-like CSCs. Our results would indicate that we have enriched
a subpopulation with high epithelial-like CSCs (Liu, Cong et al. 2014). The results of our
study are consistent with an investigation where the evaluation of 228 breast tumor
tissues revealed that Jagged1 expression was correlated with higher tumor grade,
overexpression of HER2, higher Ki-67 expression and aldehyde dehydrogenase
positivity (Bednarz-Knoll, Efstathiou et al. 2016). Interestingly, MMTV-Neu mouse
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mammary CSCs were enriched in the CD24+/JAG1- pool. The investigators found
CSCs in the CD24+/JAG1+ fraction as well, however, the frequency was lower (Liu,
Voisin et al. 2012). This could be due to Notch mediated differential effects observed
within mouse microenvironment.
Importantly, the Jagged1-high subpopulation in the absence of HER2 inhibition
did not cause the formation of CSCs suggesting that having high Jagged1 on the cell
surface is not sufficient for the formation of CSCs and that inhibition of HER2 is
necessary (Figure 12). In contrast to this, there has been a report which states that
combined inhibition of HER2 and Notch receptors effectively targets Ductal Carcinoma
In Situ (DCIS) stem/progenitor cell activity regardless of the HER2 status (Farnie, Willan
et al. 2013). HCC1954 cell line that we used for our investigation was derived from a
primary stage IIA, grade 3 invasive ductal carcinoma with no lymph node metastases.
The discrepancy observed could be due to the difference in gene signature between
ductal and invasive carcinoma.
Since HER2 inhibition resulted in an increase in the surface expression of
Jagged1, we tested whether Jagged1 transcript and Jagged1 protein were upregulated
as well. We did see an increase in the Jagged1 mRNA, however, Jagged1 protein level
was decreased (Figure 10). Since the total protein level of Jagged1 is decreased but
Jagged1 surface level is increased, it is very likely that HER2 inhibition prevents the
endocytosis of Jagged1 or enhances the recycling of Jagged1 from the endosomes
onto the cell surface. Previous work from our lab showed that Jagged1 colocalizes with
early endosome in the presence of HER2 and that HER2 inhibition by trastuzumab
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causes upregulation of Jagged1 on the cell surface (Pandya, Wyatt et al. 2016). This
suggests that possibly trafficking of Jagged1 is altered during HER2 inhibition and that
causes an upregulation of Jagged1 on the cell surface. The other possibility for
decreased Jagged1 protein upon HER2 inhibition could be the post-transcriptional or
post-translational regulation of the protein resulting in decreased synthesis or rapid
degradation of the protein.
Since the Jagged1-high subpopulation upon HER2 inhibition resulted in an
increase in CSCs, we wanted to confirm whether the effect was indeed dependent on
Jagged1. To address this, Jagged1 was knocked down using two different siRNAs
targeting Jagged1. Knocking down of Jagged1 prevented lapatinib mediated increase in
mammosphere formation suggesting that Jagged1 was indeed necessary for lapatinib
mediated enhancement of mammospheres and thus CSCs (Figure 17).
As Notch signaling has been implicated in the formation of CSCs and GSI
completely prevented the formation of mammospheres from the lapatinib Jagged1-high
subpopulation, the status of Notch activation in the Jagged1-high subpopulation upon
HER2 inhibition (lapatinib treatment) and the Jagged1-low subpopulation in the absence
of HER2 inhibition (vehicle treatment) was determined by real-time PCR. The Jagged1high subpopulation indeed had higher Notch activation (Figure 18). It was counter
intuitive that the ligand expressing i.e. signal sending cell had higher Notch activation.
Based on what we know about Notch signaling, it would be the Notch receptor
expressing i.e. signal receiving cell would be the one with the higher Notch activation.
To address this, we treated cells with or without lapatinib and then co-stained the cells
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with Jagged1 and Notch1, Jagged1 and Notch3, and Jagged1 and Notch4. Notch2 was
not used for this study as it was the least expressed amongst all the Notch receptors
and was barely detected by real-time PCR. Upon performing flow cytometry, it was
found that all the cells that express Jagged1 also expressed Notch1, Notch3, and
Notch4 (Figure 20 and Figure 21). In the context of Notch signaling, when the ligand
and the receptor are expressed on the same cell, it leads to cis inhibition, and when
they are expressed on adjacent cells, it leads to trans activation. This would raise the
question: Do we see more Notch activation upon HER2 inhibition due to increased trans
activation or due to reduced cis inhibition? To address this, a co-culture assay was
previously performed in the lab by Kinnari Pandya. HER2+ MDA-MB-453 cells, when
co-cultured in the presence of mouse fibroblasts overexpressing Jagged1 (LTK –
Jagged1), showed a significant increase in Notch activation, suggesting that HER2 is
limiting trans activation of Notch. Also, if HER2 is promoting cis inhibition of Notch
through Jagged1, then knocking down Jagged1 should relieve the inhibition and result
in an increase in Notch activation. However, when Jagged1 was knocked down in
HER2+ MDA-MB-453 or luminal B BT474 cells, it did not result in an increase in Notch
activation. These results would confirm that HER2 is not promoting cis inhibition
(Pandya, Wyatt et al. 2016). During normal development when the cell expresses both
the ligand and the receptor, the Notch activity is regulated through lateral inhibition.
Notch-Delta signaling is critical in determining the distinct fates of the neighboring cells,
whereas Jagged mediated signaling drives the cell to maintain a similar fate to that of its
neighbor (Boareto, Jolly et al. 2015). In the context of solid tumors, a recent study
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reported the involvement of Jagged1 in the lateral inhibition in glioblastoma and
pancreatic cancer model. The researchers demonstrated that when Jagged1
overexpressing cells were co-cultured with Jagged1-low cells, the Jagged1-high cells
had lower Notch activation. They found that overexpression of Jagged1 causes its
cleavage resulting in Jagged1- intracellular domain (ICD) which reduces Notch signaling
potentially through nuclear localization (Lim, Brandt et al. 2015).
Through Aim1, we demonstrated that HER2 inhibition results in the
subpopulation that has upregulation of Jagged1 on the cell surface, higher Notch
activation, and enhanced ability to form CSCs. For CSC determination, in vivo limiting
dilution assay is considered as the gold standard in the breast cancer field. The assay
involves injecting different dilutions of cells and assessing tumor take. Depending upon
the tumor take at each dilution, the CSC frequency is determined. If the population has
higher CSC frequency, then very few cells would be required to form the tumor (Hu and
Smyth 2009). Our preliminary experiment involved sorting and injecting 10,000
Jagged1-high cells after lapatinib treatment and 10,000 Jagged1-low cells after vehicle
treatment. Hundred percent tumor take was observed in the case of mice injected with
Jagged1-high cells, as compared to 33.3 percent tumor take in case of mice injected
with Jagged1-low cells (Figure 25). The data conclusively demonstrated the higher CSC
potential of the Jagged1-high population. To determine the CSC frequency of the two
subpopulations and the role of Jagged1 in affecting the CSC frequency, limiting dilution
study involved injecting 100, 1,000 and 10,000 sorted Jagged1-high and Jagged1-low
cells. The tumor take was assessed until 8 weeks and tumors ≥ 40 mm 2 were
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considered. At the end of the first week, the mice in each group were randomized and
were treated with either vehicle control or Jagged Neutralizing Antibody (CTX-014). At
the end of 8 weeks, the Jagged1-high subpopulation was found to have significantly
higher CSC frequency as compared to the Jagged1-low subpopulation. CTX-014 did not
significantly affect the CSC frequency of the Jagged1-high subpopulation. However, it
did significantly increase the CSC frequency of the Jagged1-low subpopulation (Figure
26 and Table 6). The antibody targets Jagged1 and Jagged2, and is supposed to inhibit
the binding of Jagged1 and Jagged2 with the Notch receptors. Since the antibody was
ineffective in vivo, we determined in vitro whether it affected the formation of
mammospheres or Jagged1 surface expression, and it didn’t. The possible reason for
the ineffectiveness of the antibody could be the suboptimal binding affinity of the
antibody for Jagged 1. Also, the high affinity of the antibody for the inhibitory Fc
receptors such as FcgRIIb, expressed by B-cells, macrophages, dendritic cells, and
neutrophils might decrease their overall efficiency (Chames, Van Regenmortel et al.
2009). 20 mg/kg CTX-014 has been previously shown to have the highest efficacy in
HER2/neu transgenic model and pancreatic cancer xenograft model. Since we used
athymic nude mice in the study, we cannot disregard the possibility of development of
anti-therapeutic antibodies against the therapeutic monoclonal antibody due to
immunogenicity (Kamath 2016). Rapid clearance of CTX-014 is a possibility. Another
reason could be clonal selection of Jagged1-low cells by CTX-014 treatment. The clonal
selection might cause Jagged1-low cells to express extremely high levels of surface
Jagged1, rendering the antibody ineffective.
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To determine whether higher Jagged1 on the cell surface has actual clinical
significance, we collaborated with the group in Nottingham, U.K. They stained 145
HER2+ breast tumor tissues for Jagged1 and found that Jagged1 was localized in the
membrane, cytoplasm, and nucleus. Based on the staining intensity, the samples were
classified into low Jagged1 expression or high Jagged1 expression. They assessed the
cumulative survival of each patient i.e. the time from the onset of surgery to breast
cancer related death. The results revealed that there was a significant inverse
correlation between membrane Jagged1 and overall survival i.e. higher Jagged1 on the
membrane significantly predicted poor overall survival in women suffering from HER2+
breast cancer. However, no significant correlation between cytoplasmic and nuclear
Jagged1 and overall survival of the HER2+ breast cancer patients was observed (Figure
29 and Table 7). Endocytosis of Jagged1 in the signal sending cell would result in
cytoplasmic Jagged1. The other reason for the presence of cytoplasmic Jagged1 and
nuclear Jagged1 is that just like the Notch receptors, the Notch ligands could be
cleaved by ADAM metalloprotease and gamma secretase complex following ligandreceptor interaction. This would result in the formation of an intracellular fragment of the
ligand which then translocates into the nucleus. The Jagged1 intracellular domain has
been known to regulate cell proliferation and transformation (Ascano, Beverly et al.
2003, LaVoie and Selkoe 2003, Lim, Brandt et al. 2015). The results from the patient
study clearly reveal the importance of targeting membrane Jagged1 for the
improvement of overall survival of patients suffering from HER2+ breast cancer.
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Conclusion
In the current study, we demonstrated for the first time the role of surface
Jagged1 in the enrichment of CSCs in HER2+ breast cancer. We conclusively showed
that HER2 inhibition by pharmacological or genetic means enriches membrane
Jagged1-high subpopulation that has higher CSC potential and Notch activation.
Moreover, higher membrane Jagged1 predicts poor overall survival of women suffering
from HER2+ breast cancer. Because of the plasticity between the CSCs and non-CSCs,
it is very likely that there is interconversion of CSCs to non-CSCs and vice versa.
Hence, it is critical to target both the CSCs and non-CSCs. Using combinatorial
approach involving anti-HER2 therapy along with Jagged1 targeted therapy in the
neoadjuvant setting could prevent the repopulation of the tumor and provide better
patient survival.
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➢
➢
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Therapy

Inactive
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CSC

+ Anti-Jagged1
Therapy
TUMOR REGRESSION
AND
BETTER PATIENT RESPONSE
Jagged1
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HER2
CSC

➢ Mammospheres
➢ Aldefluor Activity
➢ Notch Activation
➢ CSC Frequency
LOWER OVERALL
PATIENT SURVIVAL

Notch1/Notch3/Notch4

HER2 restricts Jagged1 surface expression. Inhibition of HER2 results in an increase in
Jagged1 surface expression. Upon HER2 inhibition, the cells that are enriched for
Jagged1 on the cell surface possess CSC-like properties and have higher Notch
activation. Moreover, higher Jagged1 on the cell surface predicts poor overall survival of
women suffering from HER2+ breast cancer. Combining anti-HER2 therapy along with
anti-Jagged1 therapy would result in tumor regression and provide a better patient
response.
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Future Investigations
Our studies demonstrated for the first time that genetic or pharmacological
inhibition of HER2 results in a concomitant increase in the surface expression of
Jagged1. The increased surface expression is responsible for the enrichment of CSCs
and predicts poor overall survival of the patients suffering from HER2+ breast cancer.
Even though the surface levels and mRNA of Jagged1 increased upon HER2 inhibition,
the level of Jagged1 protein was found to be reduced. Considering the clinical
significance of Jagged1 surface expression, the future investigation should entail the
mechanism that enhances Jagged1 surface expression upon HER2 inhibition. The role
of trafficking could be addressed by studying the interplay between dynamin, Rab4a,
Rab11a, and Jagged1. Dynamin is involved in the pinching of vesicles and is important
for endocytosis. Rab4 and Rab11a are the GTPases that are involved in the recycling of
cargo from the endosomes onto the cell surface (Stenmark 2009). Dominant negative
form of dynamin could be used to determine the role of endocytosis. If HER2 enhances
endocytosis, then blocking dynamin mediated endocytosis would result in an increase in
the surface expression of Jagged1. To understand recycling siRNA against Rab4a or
Rab11a could be used. If Rab4a or Rab11a is responsible for recycling of Jagged1 on
the cell surface, then knocking down Rab4a or Rab11a would reduce the recycling of
Jagged1 onto the cell surface.
Lipopolysaccharide and prostaglandin E2 are known to upregulate the
expression of Jagged1 in dendritic cells. Hedgehog causes upregulation of Jagged1
expression in mesenchymal cells and it is important for limb development. TGF-β
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upregulates Jagged1 expression in epithelial cells to cause EMT (D'Souza, Miyamoto et
al. 2008). Beta-catenin is known to upregulate the transcription of Jagged1 in colorectal
cancer and ovarian cancer (Rodilla, Villanueva et al. 2009, Chen, Stoeck et al. 2010). It
would be important to determine if any of these effectors are critical for the
transcriptional upregulation of Jagged1 upon HER2 inhibition.
To address the possibility of clonal selection versus expansion of Jagged1-high
subpopulation of cells, lineage tracing could be performed. A stable HCC1954 cell line
that expresses GFP can be created (HCC1954-GFP). HCC1954-GFP cells can be
stained with Jagged1 and the cells expressing high Jagged1 on the cell surface can be
sorted. Similarly, HCC1954 parental cells can be stained with Jagged1 and the cells
expressing low Jagged1 on the cell surface can be sorted. The sorted HCC1954-GFP
Jagged1-high cells can then be co-cultured with HCC1954 parental Jagged1-low cells.
These co-culture cells can then be treated with 2 μM lapatinib or vehicle control for four
days. Followed by the treatment, the cells can again be stained with Jagged1. The
Jagged1 and GFP staining of the cells could be examined by flow cytometry. We know
that lapatinib treatment increases Jagged1 expressing cells on the surface. If the
lapatinib treatment results in surface Jagged1 expressing cells that are only GFP
positive, that would indicate clonal expansion of Jagged1-high cells. However, if the
surface Jagged1 cells upon lapatinib treatment contains a mix of GFP positive and
negative cells, then that would indicate the possible conversion of Jagged1-low cells
into Jagged1-high cells.
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To understand the plasticity of CSCs, similar lineage tracing approach could be
utilized. HCC1954 GFP cells could be treated with lapatinib and stained with Jagged1.
The HCC1954 – GFP cells can then be sorted for Jagged1-high surface expression.
Similarly, HCC1954 – YFP stable cell line can be created. HCC1954 – YFP cells can be
stained with Jagged1 and Jagged1-low cells can be sorted. Like the pilot experiment
that we performed for the in vivo study, 10k HCC1954-GFP Jagged1-high cells and 10k
HCC1954-YFP Jagged1-low cells can be injected into the mice. After the tumor
formation, the tumor could be excised and tumor cells could be dissociated. The
dissociated tumor cells could then be examined for GFP or YFP expression. If all the
cells are not YFP or GFP positive, that would indicate the tumor heterogeneity.
Extensive proteome analysis should be performed using the dissociated tumor cells
(GFP+, YFP+, and GFP-YFP-). The proteome analysis would give a better idea
regarding the differences in the cell signaling networks and potential drivers of the
CSCs and non-CSCs.
Jagged1 neutralizing antibody that we used for the in vivo study was not able to
effectively block Jagged1. In the future, it would be critical to develop therapeutics
targeting Jagged1. Small molecule inhibitors targeting the binding of Jagged1 with the
Notch receptor that is involved in mediating CSCs would prove to be beneficial.
Moreover, newer approaches like exosomes or nanoparticles mediated Jagged1 siRNA
delivery could be tried for effectively targeting Jagged1 (Cong-fei Xu 2015).
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